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ABSTRACT
Atrial fibrillation is the most common type of irregular heartbeat. It is associated
with substantial health risks, limited treatment success, and high relapse rates, and this
chronic condition is difficult to diagnose due to transient symptoms or absence of such.
Atrial fibrillation has important public health implications as it adversely affects one to two
persons per hundred in psychological, social, and economic terms.
The objective of this research was to quantitatively describe the patient’s journey
towards the diagnosis of atrial fibrillation within an episode of illness framework. Electronic
medical records were accessed through the DELPHI database. The patient’s lived
experience was analyzed with descriptive statistics in terms of the number of physician
visits, episode length, medications prescribed, diagnostic investigations ordered, and
referrals made. The observed findings were compared to a control group of patients with
other chronic conditions. The differences between the two groups were statistically
significant, with an overall large effect size.
The emerging knowledge of a patient’s journey may identify patients’ unmet needs
and inform future public policy development in the diagnosis and management of atrial
fibrillation.
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CHAPTER ONE – INTRODUCTION

1.1 Thesis Overview
The overall objective of this thesis was to quantitatively describe the lived
experience of patients diagnosed in primary care with the most common sustained
cardiac arrhythmia called Atrial Fibrillation (AF).
It is important to capture the disease experience from the patients’ in addition to
health care providers’ perspective for several reasons. First, AF is accompanied by
substantial health risks and patients deal with uncertainty around the diagnosis of AF. .
This ongoing uncertainty can significantly affect patients’ quality of life1. Furthermore,
despite the patient’s high compliance with the treatment protocol, the achieved success
is limited and relapse rates are high. Second, AF has public health implications because
it affects one to two persons per hundred not only physically but also in psychological,
social and economic terms. Third, due to ambiguous and transient symptomatology or
absence of such, AF is difficult to diagnose, thus leading to a protracted assessment
period. This adds to emotional distress and significantly disrupts daily living of AF
patients and their families as well as delays the start of evidence-based disease
management.
Health service researchers have devised a concept called the episode of care that
is suitable for studying the experience of people with a health condition. While there
exist different definitions, the one operationally used in this thesis is the time-period
from the first ICPC-coded outpatient encounter as a starting point to the date of
diagnosis as an end-point. This definition was applied using a sophisticated ICPC-coded
portion of the DELPHI database (Deliver Primary Healthcare Information). As a result,
we identified69 primary care patients that were seen by 23 physicians in 10 practices
over a ten-year period (2006-2015). The ten-year prevalence of AF in the DELPHI
database (including the ICPC-coded portion) is 3.1% in the patient population of 48,387
individuals (Appendix K). Approximately 10% of the DELPHI patient population was
coded using ICPC and the ten-year prevalence of AF among the ICPC-coded population
of 4,838 persons is 1.98%, i. e.., with 69 identified cases. In other words, 23 family
1

doctors in 10 practices diagnosed AF in 69 out of 4,838 ICPC-coded patients over a span
of 10 years.
The following variables pertaining to the length of time between the first
outpatient medical encounter and the final diagnosis within an episode of illness were
studied: 1) the number of physician visits; 2) the episode length; 3) the number and type
of medications prescribed; 4) the number and type of diagnostic investigations ordered;
and 5) the number and type of referrals made.
The thesis is organized as follows. Chapter 2 contains a review of the literature
on AF as well as the concepts of an outpatient medical encounter and an episode of care.
It is followed by the description of the Methods used in Chapter 3. Chapter 4 contains
the results of the analyses whereas Chapter 5 is devoted to Discussion and Conclusion.
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CHAPTER TWO – LITERATURE REVIEW
This chapter will present the review of the published literature on the
epidemiology of AF, the concepts of outpatient medical encounters, episodes of illness,
symptomatology and methods for detecting AF as well as touch upon early drug therapies
prior to the confirmatory diagnosis of AF.

2.1 Overview of AF
Being the most common sustained cardiac arrhythmia, AF affects 1-2% of the
general population.2, 3 Aging is associated with an increased risk of developing AF,
potentially through age-related isolation and loss of atrial myocardium.4 Thus, at the age
of 40-50, the prevalence of AF is less than 0.5% whereas between 65 and 69 years of
age, it is 2%5 and at 80 years, it increases up to 8-15%.3, 2, 6, 7, 8 Within the next 50 years,
as the population ages, the prevalence of AF is expected to double.4 Men are usually
more affected than women. AF, especially of an early onset, has a genetic
predisposition.9
The classical risk factors for developing AF include cardiac and non-cardiac
conditions such as ischaemic cardiomyopathy, valvular disease, hypertension, thyroid
disease and diabetes10. Parental AF as a risk factor for AF in offspring9 is also present.
The findings of the study conducted by Fox et al.9 demonstrated that a familial
component predicted an increased risk of offspring AF, after having adjusted for other
standard AF risks with genetic components (i.e., diabetes, hypertension, and myocardial
infarction).
In some patients, AF (also known as lone AF) has an idiopathic aetiology, with
no underlying pathology. In recent years, however, clinicians and researchers started
talking about “not-so-lone atrial fibrillation”11 and evaluated “new risk factors”11 as
playing a role in the genesis of AF. Among the “new risk factors”11 (as juxtaposed to the
classical risk factors) are overweight and obesity, sleep apnea, sedentary life style, its
counterpart – excessive sports practice, inflammation, latent hypertension, abuse of
alcohol and other substances.
3

AF is an independent risk factor for stroke: in its presence, the risk of stroke is 5
times higher and increases with age.5 Ischaemic strokes in combination with AF lead
twice as often to fatalities, and survivors are more disabled by their stroke and more
likely to experience a recurrence than patients with other stroke causes.4, 12
AF is associated with increased rates of heart failure and hospitalizations.4
Cognitive dysfunction,13 impaired quality of life14 and reduced exercise capacity15 are
other negative consequences that AF patients experience on a daily basis.
Approximately 67% of all emergency department visits with a primary diagnosis of AF
get hospitalized to acute inpatient units.16, 17
A retrospective cohort study of emergency department patients with a primary
diagnosis of AF18 over an eight-year period (2002-2010) in the province of Ontario
found that the frequency of AF as well as proxy measures for its severity (CHADS2
score and triage category) increased. There was a relative increase of 29% in the number
of AF-related emergency department (ED) visits in 8 years. This increase included
approximately 20% of patients who were readmitted to ED for AF18. Over time,
however, the admission rates decreased, accounting for 0.5% of all ED visits. The
authors attributed the observed increase partly (about 15 % of the increase) to aging of
the population18. Another possible explanation suggested by Tu et al.19 - as they
analyzed mortality data from Statistic Canada's Canadian Mortality Database for the
period of 1994-2004 – is longer survival of patients with congestive heart failure,
myocardial infarction, and stroke. AF is also associated with a number of medical
conditions that are risk markers rather than solely causative agents.4 Among the
comorbidities are both various cardiomyopathies20, 21, 22 and other medical conditions.
Based on their prevalence in the general population, it is worth mentioning the following
disorders : diabetes mellitus4 (20% of AF population); chronic obstructive pulmonary
disease (COPD) (10-15% of AF population)4; obesity (25% of AF population)21;
hypertension, sleep apnea and chronic renal disease (10-15% of AF patients).4 Although
relatively uncommon in the AF population,20, 21 thyroid dysfunction alone can cause AF
and AF-related complications.

4

Management of AF patients is dependent on the type of AF which, in turn, is
based on clinical presentation and duration of the arrhythmia.4 Specifically, antithrombotic treatment protocol is dependent on the definition of the valvular (rheumatic)
versus non-valvular (hypertensive) origin of AF23. There are five main types of AF:
paroxysmal, persistent, long-standing persistent, permanent and silent AF (Figure 1).4
A patient presenting with AF for the first time is deemed to have first diagnosed
AF. Paroxysmal AF terminates by itself usually within 48 hours of onset. Although AF
paroxysms can last up to 7 days, the 48-hour time window is clinically relevant for the
management of AF.
After 48 hours, sinus rhythm is not likely to spontaneously return and
anticoagulation therapy must be implemented. First of all, to improve cardiac
performance and to alleviate symptoms24, there may be a need for pharmacological (for
recent-onset AF) or electrical cardioversion (for prolonged AF). Unfortunately,
cardioversion is an inherent risk factor for thromboembolism25. The risk associated with
cardioversion can be minimized from 5-7%26 to less than 1%27 with prophylactic
anticoagulation therapy. Anticoagulation is highly recommended before and after
cardioversion. The traditional anticoagulant has been warfarin24. Recently, after having
demonstrated their non-inferiority to warfarin in clinical trials28, the direct oral
anticoagulants have also been approved24.
When an AF episode lasts longer than 7 days or cardioversion is used to
terminate it, the diagnosis is persistent AF.
Whether rhythm control management is desired or not, there distinguish two
more types of AF: long-standing persistent AF and permanent AF. Long-standing
persistent AF lasts longer than one year and a rhythm control protocol is adopted. With
permanent AF, its existence is recognized by the patient and the physician and there is
no pursuit of rhythm control interventions.
Finally, silent AF is asymptomatic in nature and is often diagnosed by an
opportunistic electrocardiogram (ECG). Silent AF can be of any temporal form of AF.
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Because the objective of this thesis was to quantitatively describe a patient’s
journey to the diagnosis of AF and based on the available data, the emphasis was on first
diagnosed episodes of AF, without further distinguishing its subtypes.

Figure 1: Types of Atrial Fibrillation1

1

Source: Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial
fibrillation. Eur Heart J. 2010;31(19):2369-2429. doi:10.1093/eurheartj/ehq278
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An irregular pulse can be indicative of the underlying AF in individuals
presenting with chest pain, palpitations, breathlessness and dizziness.29, 30, 31, 32 At the
same time, AF can present with a variety of non-specific symptoms that may differ not
only between patients but in the same individuals over time.15 At the opposite end of the
spectrum are asymptomatic cases and this proportion can be as high as 15% -30% of the
AF population15, 33, 34, 35. Indeed, many patients in a primary care setting remain
asymptomatic at the time of their first encounter with their family physicians.36
It is key to identify, assess and diagnose patients with AF, especially the
asymptomatic cohort, so that they can receive prompt treatment.36 The recommended
strategy for early detection and management of AF is to perform opportunistic (≥65
years), routine (known risk factors or cardiovascular disease) or triggered (suspicious
symptoms or palpitations) screening in general practice 29,37. Once patients are
diagnosed with an underlying cardiovascular disease, hypertension and diabetes, it is
prudent to assess them for the presence of AF. For pragmatic purposes, screening in
primary care is easy to conduct since such patients regularly see their family physicians
for routine check-ups.36 In order not to miss an opportunity of diagnosing the preexisting AF and giving timely antithrombotic treatment to patients at risk,36 it is good
practice to check blood pressure and pulse. Antiarrhythmic therapy is also appropriate
for specific case scenarios: for symptomatic, young, active patients, and in recent-onset
AF)38.
General management of AF includes the following five strategies:4 1) antithrombotic treatment; 2) relief of symptoms; 3) ventricular rate control; 4) management
of cardiovascular comorbidities; and 5) maintenance of sinus rhythm. However, the
recent research39 has demonstrated no clinical value of rhythm disturbance correction.
Strict rate control therapy has not been proven advantageous, either.4 Unfortunately,
‘upstream’ drug therapies and life style modification strategies (exercise, diet, fish oil)
aiming at delaying or preventing myocardial remodeling, have also achieved modest
success.40 A modest treatment effect and high rates of reoccurence41 are accompanied by
other negative consequences such as psychological, social, economic and employmentrelated.
7

2.2 The Concept of an Outpatient Medical Encounter

An encounter (visit) in a primary care setting starts with a patient presenting with
one or more reasons for the encounter, either in the form of a symptom or complaint, a
diagnosis or a request for an intervention, such as filling prescriptions, advice or a
referral to a specialist.42 The family physician establishes the most likely diagnosis and
performs one or more interventions. Sometimes, on the basis of a most probable
diagnosis, the doctor monitors the patient by so-called “watchful waiting”43, 44 This
widely accepted representation of the doctor–patient encounter is considered to be an
international standard approach. 45, 44
From the health care system standpoint and for billing purposes, a patient-doctor
encounter constitutes a face-to-face documented visit during which the provider (doctor)
exercises an independent judgment while providing services to the client (patient). The
encounter criteria are extended to such services as X-rays, prescription refills,
vaccinations and laboratory tests. In order to be classified as an encounter, services
rendered must be billed.
In this research, an outpatient medical encounter is defined as an in-office
physical contact during which the family physician provides any medical service to the
patient. Each date of service in a primary care setting constitutes a separate encounter,
i.e., one “billable” medical encounter per patient per day. Although there exist different
provider types, in the DELPHI database the provider is a general practitioner who is
primarily responsible for assessing the patient and documenting the services rendered in
the patient’s electronic medical record (EMR). The patient (user, client) is defined as an
individual who had at least one encounter. Each patient is counted only once regardless
of the number of services received.

2.3 The Concept of an Episode of Illness
The literature recognizes different types of episode concepts46, 47 . There exist
four distinct perspectives on the definition of a health care episode 48: 1) an episode of
8

illness or indisposition (from the patient’s perspective); 2) an episode of disease (from
the care provider’s standpoint); 3) an episode of care (from the payer’s or the health care
system perspective) and 4) a health maintenance episode (from the societal perspective).
Each episode, regardless of its type, has a defined starting and end-point and the
end-point is the same for all types – disease resolution or patient’s death. It is accepted
in the literature, however, that some diseases (for instance, chronic conditions) may be
open-ended, with no discrete starting and end-points.46 In such a case, based on its
technologic feasibility, the treatment is shifted from “cure” or “resolution” to
“maintenance” or “palliation”.
From a patient’s perspective, an episode of illness or indisposition entails a
continuous time-period that the patient is suffering from a medical condition. The patient
may experiences a continuous spell of symptoms that are perceived as ill-health46.
Symptoms are experienced and reported by the patient (subjective) whereas signs are
observed by the health care provider (objective).
From a care provider’s perspective, an episode of disease constitutes a timeperiod that starts at the disease diagnosis and ends at its resolution or until the patient’s
death49.
From a payer-centric standpoint, an episode of care is a set of associated
healthcare services to the diagnosis and treatment of a complaint. The broad definition
of an episode of care refers to a health problem from its first to the last encounter with a
family physician49.
Health maintenance episodes describe encounters with the health care system
that do not involve an illness or a disease46: health promotion, cosmetic procedures,
employment-related physical examinations, etc.

9

Figure 2: Types of Heath Care Episodes
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The episode of care concept is easily defined for acute-onset events such as hip
fracture, but more challenging to use to capture the patient’s experience of AF,
particularly in the stressful time before the definitive diagnosis. This is because the
specific encounter that eventually led to the diagnosis may have been for one or more of
the many non-specific symptoms of AF.
To capture the patient’s experience towards the diagnosis of AF, an episode of
illness is operationally defined as a time-period from the first ICPC-coded encounter as
a starting point to the date of diagnosis as an end-point. Episode-framed patient data
allow a more thorough evaluation of the degree to which family practitioners are
involved in a vast majority of patient’s health care needs49. The notion of an episode of
illness also enables to capture the patient’s lived experience.
Relevance of a medical encounter to the diagnosis of AF will be determined
based on reasons for encounter as reported by patients. Although symptomatology is a
major reason for patients with AF to see their family physicians,15 other reasons for
encounter may be in place: for instance, medication renewal, regular check up, blood
tests, preventive immunization, etc. From the established diagnosis of AF, we will
attempt to retrospectively cluster different encounters into an episode of illness.
All the encounters within the patient’s electronic medical record are considered
for inclusion into an episode of illness and apparently unrelated ones (“sprained ankle”,
“frozen shoulder”, etc.) are excluded from the subsequent analyses.
An episode is a meaningful unit of analysis for evaluating primary services
utilization in treating a particular health problem. Episode-of-care analyses have been
conducted in a wide range of studies50 assessing the efficiency and quality of care;
evaluating charges in different clinical settings; exploring physician referral patterns and
patient resource utilization. Studies of the effect of cost-sharing on patient behavior50 also
used the concept of an episode of care as a unit of analysis.
The framework of an episode of care has the potential of better reflecting general
practice care, overall46, and a patient’s journey, in particular. It allows us to maintain
the continuity of care dimension51 which is not the case with, for instance, a commonly
used visit-per-visit framework of analysis. Family physicians provide not only personal,
11

but also factual continuity of care. As far as the personal component is concerned, the
patient presents to the doctor with any health-related problem at any stage of
development49. The factual continuity of care, on the other hand, is much broader in its
scope: the physician keeps the medical health records of the patients up to date in a
structured manner, over a period of time, while accounting for professional field and
societal changes49.

2.4 Symptomatology in Atrial Fibrillation and Associated Challenges
For any disease, symptom report is key as it drives medical care, serves as
motivation for treatment adherence and serves both as a clinically relevant outcome for
patient care and a benchmark in clinical decision-making.52 Accurate symptom reporting
could improve symptom palliation and differential diagnosis.
Despite the fact that AF was first recognized as early as in 1906,53 its
symptomatology has not been thoroughly evaluated.52 Signs and symptoms ˗ generic and
disease-specific ones - have a great variability in AF35. Some patients have no
symptoms, and the condition is discovered incidentally. In others, the generic symptoms
can be clinically presented by weakness, fatigue, dizziness and exercise intolerance. The
disease-specific symptoms include heart palpitations, chest pain, pressure or discomfort
and shortness of breath. Until now, there has not been developed a “gold standard” in
terms of standardized assessment of AF-related symptoms. This lack of standardization
can have a detrimental effect on management of AF as decision-making in AF is
primarily symptom-driven.54 Additional challenges arise due to high variability of
symptoms not only among patients but also in individual patients at different points in
time15.
In the Euro Heart Survey of Atrial Fibrillation,55 69% of patients presented with
AF-specific symptoms. Fifty-four percent of currently asymptomatic patients had
experienced AF symptoms in the past .20 Holter 24-hour monitoring demonstrated that
patients with symptomatic paroxysmal AF were 10-fold more likely to have an
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asymptomatic versus a symptomatic recurrence.52 Overall, many patients’ experience
consists of both symptomatic and asymptomatic episodes of AF.56, 57, 58, 59
Although patient symptoms are extremely important in detecting and treating
AF,52 they have no diagnostic capacity for “silent” AF. The proportion of asymptomatic
AF patients is approximately between 15% and 30%.15, 33, 34, 35 A few studies showed
that 65% of documented AF episodes are not associated with any symptoms in nature.60
Notwithstanding “silent” AF, there are other reasons that make patient symptoms
an unreliable diagnostic tool. In a study of 518 consecutive 24-hour electrocardiographic
recordings,61 less than 10% of patients reported palpitations accurately. The researchers
of this study also found little correlation between the type of arrhythmia and the specific
nature of the patient’s symptoms.61 It is widely recognized in the literature that a cardiac
pathology and symptoms do not correspond on a one-to-one, fixed basis.62
Patients with a history of AF often report symptoms attributable to AF when in
normal sinus rhythm.52 In other words, there are many patients with palpitations that do
not have arrhythmias.62 The transtelephonic monitoring study by Bhandari et al.63
demonstrated that 69% of symptomatic patients were recorded to have arrhythmia.
Thirty-one percent of those patients who complained of AF symptoms had normal sinus
rhythm.63 In a later study, Gerstenfeld et al.64 confirmed that AF-specific symptoms
could equally occur in normal sinus rhythm versus AF. Furthermore, a patient with AF
is treated to achieve ideal rate control that minimizes arrhythmic symptoms.
Alongside physiologic variables, such psychological variables as anxiety, stress
and depression come into play. Symptom-wise, there is a lot of overlap between
psychological distress and AF. Furthermore, a panic attack can not only mimic AF
symptoms but also aggravate them. Unfortunately, no systematic evaluation of both
physiologic and psychological variables that might affect patient-reported AF symptoms
has been conducted to date.52
Other cardiovascular comorbidities, such as heart failure and valve disease, in
combination with AF produce similar symptoms.15 It is difficult to dissect AF-related
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symptoms from the symptoms caused by co-morbidities: heart failure may be secondary
to AF and vice versa
In cardiology, the term “palpitations” is sometimes referred to as a “bland label”
that requires further operationalization.65 Palpitation is defined as a sudden awareness of
one’s heartbeat. It can be described as skipping, racing, stopping, pounding, or
fluttering.62 By its nature, the term is vague and ambiguous65 and neither physicians nor
patients explicate the precise meaning in which they use the term. As a result, an
electronic medical record database is filled with “symptoms within symptoms” or
“information within the information”62 that needs to be accounted for in the research
process. At the stage of analysis, per se, there is an important requirement to precisely
define a set of potential predictive variables.
The majority of symptomatology studies were conducted on hospital-based
cohorts or on subjects referred for AF assessment.15 Consequently, the study results can
have limited generalizability: hospital-based cohorts may be different from populationand community-based cohorts.36 In hospital-based studies, the risk of selection bias is
high. This is particularly true since many patients either present to hospital due to an
associated comorbidity or do not go to hospital at all.
There are major gaps in knowledge about whether there is a clinically relevant,
mechanistic link between symptoms and the final diagnosis of AF in primary care.66, 50
Little is known about the patient’s experience of AF in relation to functional status and
magnitude of symptoms in general practice. Symptoms may be non-specific for AF (for
instance, anxiety and fatigue).15 It is often the case when the patient has other
cardiovascular comorbidities. Risk factors for AF and comorbidities can initiate similar
symptoms. Research is complicated by the fact that AF is often accompanied by valve
disease and heart failure – the two conditions with similar symptomatology.15
Heart failure is common in AF patients as both diseases have major risk factors
in common, such as diabetes mellitus, myocardial infarction, valve disease and
hypertension.67 Furthermore, each condition can predispose to the other one: AF
predisposes to heart failure and vice versa. The ‘safe’ conclusion would be that
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symptoms attributable to AF are multifactorial due to their direct and indirect effects of
the underlying arrhythmia.15
Physicians already predict the presence of AF from different sources – albeit
non-quantitatively and informally.68 Their decision-making is based on diagnostic
investigations, physical examination findings and on patient’s symptoms and observed
signs. Identifying symptom patterns can be important in predicting the diagnosis of AF
for the selected patient populations and in defining clinical states for individual
patients.68
Using the database of the Transition Project, Lamberts et al.66 calculated
posterior probabilities (in the form of an odds ratio) of the final diagnosis in general
practice. The International Classification in Primary Care (ICPC) was used to code both
the reason for encounter and the diagnosis. As a result of the Transition Project, a
database with a total of 201,127 patient-years for the period of 1985-2002 was created.66
The question of interest was whether there was a clinically relevant relationship
between two simultaneously occurring events – a symptom and a diagnosis – in general
practice. Out of a few conditions, the highest odds ratios of 32.5 were reported for AF.
These results are promising as the high value of posterior probability is indicative of the
clinical relevance of physician observations.
The posterior probability approach enabled the authors to determine the clinical
relevance of general practitioners’ observations and only ‘certain’ or verified diagnoses
were used in the calculation.66 Symptoms as predictive variables for the diagnosis
provide evidence-based support for clinical work. With calculated posterior probabilities
for primary care,66 it is possible to determine whether a specific symptom plays an
important role in diagnosis while another symptom contributes little or nothing to it.
2.5 Symptomatology
Based on the literature review, the following symptoms related to AF were
distinguished: 1) palpitations; 2) chest pain or discomfort; 3) shortness of breath; 4)
reduced exercise capacity, and 5) dizziness.
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Palpitations, or increased awareness of heartbeat irregularity: More than 50% of
patients with AF report having palpitations or are aware of their heartbeat irregularity.
Even though the correlation of palpitations with arrhythmia was the strongest of all other
AF-related symptoms (palpitations occurred more frequently during AF (67%) versus
sinus rhythm (24%))52, the value of 67% is far from definitive for the diagnosis
establishment.
Interestingly, but not surprisingly, the perception of arrhythmia (not its presence)
and neuropsychiatric variables are strongly correlated. It is conceivable that a patient
experiencing anxiety or a negative emotion is more likely to report arrhythmia when in
normal sinus rhythm.52 Psychological distress potentially augments a patient’s
perception of ill-health and disease symptomatology.52
Chest pain or discomfort: Chest discomfort, pressure and pain often occur during
AF episodes even in the absence of structural heart diseases69 such as critical valve
disease or coronary disease.70
Dyspnea or shortness of breath: Dyspnea is an indirect consequence of AF15 and
can be accompanied by any type of intracardiac pressures – low, normal and elevated.70
It is commonly accepted that elevated intracardiac pressures can initiate ventricular
arrhythmias71. In vivo humans and in isolated hearts, acute ventricular dilatation has
potentially arrhythmogenic effects71
Exercise intolerance or reduced exercise capacity: As measured by New York
Heart Association,72 over 50% of AF patients experience reduced exercise capacity.
Reduction in exercise performance may be due to dyspnea or may be non-specific.73 The
New York Heart Association classifies cardiac patients based on the clinical severity and
prognosis of their conditions and distinguishes four classes of functional capacity.
Functional capacity is an estimate of how much physical activity the patient’s heart will
tolerate and is based entirely on subjective symptoms72 The status of cardiac functional
capacity informs subsequent management of the patient’s activities . Similarly to
dyspnea, patients may have reduced exercise capacity due to arrhythmia with low or
even normal intracardiac pressures.74 Dizziness, syncope and presyncope are rarely
reported by patients with AF.15
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2.6 The Concept of Symptom Clusters
Symptom clusters have long been used for diagnostic purposes in general
medicine. Even though a medical diagnosis is ultimately dependent on diagnostic tests,
symptoms still play a fundamental role in disease detection.75 By understanding
symptom clusters, clinicians can develop more accurate and comprehensive diagnostic
tools.75
A symptom cluster consists of two or more concurrent symptoms that are related
to each other and may or may not share common etiology. This definition requires
further clarification:75
1) In terms of the number of symptoms within a cluster, the presence of at least
two symptoms serves as an antecedent for a symptom cluster.
2) The meaning of symptom is extended to include both signs (objective,
observed by the clinician) and symptoms (subjective, self-reported by the patient).
3) A symptom cluster consists of a stable group of symptoms, i.e., symptom
patterns that are replicated across time and subjects. In case of AF, stability of symptoms
cannot be easily achieved due to high inter- and intra-individual variability,15 yet needs
to be assumed for diagnostic purposes.75
4) Each symptom cluster is relatively independent of other clusters.
5) The relationships among symptoms within a cluster should be stronger than
the ones across clusters. Otherwise, the symptom cluster could not identify specific
underlying dimensions of symptoms.
6) Etiology in the context of general medicine refers primarily to the underlying
biological mechanism of a symptom.

2.7 Atrial Fibrillation-Specific Symptom Clusters
As a new area of cardiovascular research,76,77 symptom clustering is a group of
two or more related symptoms due to shared underlying mechanism, common effect on
outcomes and covariance.78, 75 Several researchers not only identified symptom clusters
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but also described an association between cardiovascular symptom clusters and
outcomes of interest.76, 79, 8081
Gaps in knowledge in regards to AF symptom clustering make it difficult for
physicians to develop appropriately individualized, patient-centred treatment plans.78
Therefore, additional information gained from cluster analysis can be used to tailor
management approaches to the needs of an individual patient.
Cardiovascular symptom clustering has already been explored in a number of
studies77, 78, 76. Some researchers went beyond the strictly descriptive aspect of cluster
identification and analyzed symptom clusters for their association with outcomes of
interest. Thus, Song et al. explored possible associations between symptom clusters and
event-free survival in 421 patients with heart failure.79
The study by Hwang et al.80 attempted to answer the question of whether atypical
symptom clustering predicts a higher mortality in 391 patients with first-time acute
myocardial infarction. Finally, a few years later the same researcher explored the
relationship between cluster dyads of risk factors and symptoms and major adverse
cardiac events (MACE) in 522 patients with acute myocardial infarction.81 The outcome
of interest was the incidence of 12-month MACE after the myocardial infarction81.
Based on the association between the risk factors and symptom clusters, Hwang and
Kim identified six cluster dyads and confirmed them to be a significant predictor of 12moth MACEs. The incidence of adverse cardiac events was three times higher in the
hypertension/diabetes/atypical symptoms dyad than in the dyslipidemia/smoking/typical
symptoms dyad. In their analyses, the researchers accounted for age, gender, and a type
of MI diagnosis. The study results suggest that, in order to prevent MACEs via risk
stratification, clinicians need to take into consideration both symptoms and risk factors
at clinical presentation81.
In application to AF, Streur and her colleagues78 identified AF-specific
symptom clusters in 1501 adults, characterized individuals within each cluster and
assessed cluster association with an end-point of healthcare utilization. Patients’
utilization of heath care services was defined as the number of emergency department
(ED) visits, AF-related hospitalizations and cardioversions patients had within the past
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12 months.78 The researchers identified two clusters that met the definition of a
symptom cluster (two or more simultaneously occurring symptoms) and labelled them
as 1) the Weary cluster (shortness of breath at rest, fatigue at rest, dizziness, and chest
pain) and 2) the Exertional cluster (dyspnea with activity and exercise intolerance). The
most common symptoms were exercise intolerance (42%), dyspnea with activity (40%)
and palpitations (33%).
Another study used participants from the SAFETY trial77, 82 and identified AFspecific symptom clusters that differed from those in the study by Streur et al.78 In the
order of their frequency, the clusters from the SAFETY trial were labelled as: 1) the
heart cluster (palpitations/fluttering and chest pain/discomfort): it was the most common
symptom cluster occurring in 26% of participants; 2) the tired cluster
(dyspnea/breathlessness, syncope/dizziness, weakness, fatigue/lethargy): all the
symptoms were present in 14% of the subjects; 3) the vagal cluster (diaphoresis and
nausea) occurred only in 3 patients. Over 50% of the participants with the tired cluster
also reported experiencing the heart cluster.
In spite of the differences in the number and composition of the clusters, the
palpitations cluster78 or the heart cluster77, 82 was still the most common in both studies.
The tired cluster and the weary cluster demonstrated the most similarity as they differed
by only one symptom: chest pain was used in the weary cluster whereas in the tired
cluster, weakness as a symptom was embedded. The observed differences in the clusters
may be attributable to inclusion criteria, measurement error as well as recruitment
strategies employed in both studies.78 These identified clusters have yet to be replicated.
Although AF-specific symptom research is an emerging field,77, 76 some studies have
already identified symptom clusters among AF patients76 and their relationship with
health outcomes.79, 80, 81

2.8 Clinical Assessment of Atrial Fibrillation
To determine efficacious management of AF, it is essential to understand the
underlying development of AF-related symptoms, i. e., how AF-related symptoms
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change over time.15 Symptom fluctuation poses the biggest challenge when symptom
patterns vary not only in different AF subsets but also in an individual patient.54, 52, 83
Given the considerable variability of symptoms and their severity as well as
treatment dependence on individual circumstances,36 a patient with suspected AF needs
to undergo a thorough clinical assessment. Clinicians have to manage patients presenting
with a variety of symptom severity, yet with “substantively similar physiology”.70 The
hardest aspect of diagnosing AF is that the correlation between symptomatology and
objective findings varies a lot for any given patient.70 As a result, it is challenging for
clinicians to distinguish a set of typical cases to expect in terms of clinical manifestation
in patients with AF.
At the stage of clinical assessment of AF, one aims at establishing the type of
AF, its etiology and time of onset. 36 It is important to explore major comorbidities and
potential complications which would, in turn, affect the suitability of future treatment
plans.
The existing research provides very limited, if any, information on mapping the
patient journey after the first visit to the general practitioner. Little is known about the
sequence of decisions made “to identify, assess, manage and monitor patients with AF”.29
Knowing common patient care pathways is crucial, particularly because they are evidencebased and as such provide a “guide to the guideline” by informing clinician’s decisionmaking. Unfortunately, multiple versions of guidelines for AF – both in North America and
Europe – hardly reflect on real-life context within the primary care framework. While the
clinical literature is rich and extensive, the individual variability mentioned in most
guidelines underscores the need for a better understanding of the patient experience.

2.9 Methods for Detecting Atrial Fibrillation
The major methods currently used to identify pulse irregularity caused by AF can
be classified in the following groups: 1) pulse palpation;37, 84, 85, 86, 87, 88 2) blood pressure
monitors (BPMs);84, 89, 90, 91, 92, 93 3) and ECG37, 94, 95, 96, 97, 98, 84, 99, 87, 100.
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In accordance with current guidelines,101, 102 pulse palpation should be used as
the first step in screening for AF. Two randomized controlled trials in a primary care
setting evaluated pulse palpation in combination with confirmatory 12-lead ECG and
found it to be a cost-effective and efficacious method of AF screening.37, 86
Nevertheless, pulse palpation is thought to be the least diagnostically accurate
which is reflected by its lower specificity.103 This tendency can be explained by interobserver reliability when health care professionals are required to classify the pulse as
being normal or irregular.103
The range of sensitivity in most studies on pulse palpation was high: between
91% and 100% whereas the specificity ranged from 70% to 77%. The pooled results of
positive and negative likelihood ratios5 demonstrated that pulse palpation could
moderately help in ruling in AF. However, in all the studies, the patient population was
older than 65 years and the pulse was taken by a nurse, not a general practitioner.
Therefore, it is difficult to generalize these findings to younger patients, with their pulse
rate taken by a physician.
Blood pressure monitors overcome the limitation of inter-rater reliability that can
be misleading in the pulse palpation method. Any electronic device, including BPMs,
uses rigid software algorithms with predetermined cut-off points. The BPM determines
the severity of irregular pulse and classifies patients as meeting or non-meeting the
inclusion criteria for AF. As a result, other non-AF-related causes of pulse irregularities
are excluded by the software algorithms.103
When compared to pulse palpation, BPMs are much more accurate in detecting
patients with suspected AF. In a primary care setting, the use of BPMs is commonly
advocated among patients being monitored for hypertension.104 Apart from being
“simple, quick and accurate”, BPMs are also cost-effective and do not require any
additional training. Since blood pressure monitoring is already integrated into
cardiovascular screening protocols in primary care,103 BPMs can be a pragmatic
substitute for pulse palpation.
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The diagnosis of AF requires rhythm recording demonstrating irregular rhythm
in the absence of organized atrial activity. The 10-second 12-lead standard ECG cannot
register the typical episode of AF that lasts ⩾ 30 seconds. Ironically, for most trials that
formed the evidence for guidelines, ECG-diagnosed AF was an inclusion criterion.
However, following the 2007 consensus document on catheter and surgical ablation of
AF that was adopted by the Heart Rhythm Society, the European Cardiac Arrhythmia
Society and the European Heart Rhythm Association105, AF is defined as an arrhythmia
lasting ⩾ 30 seconds106. Furthermore, the thirty-second gold standard definition of AF may
lead to various predictive implications when detected on a 24-hour Holter monitor versus
an implanted device106.

For chronic forms of AF, ECG is a cost-effective and effective method of prompt
recording of irregular heart rate.107 Substantive evidence also confirmed the
effectiveness of ECG recording for silent, undetected AF. This type of AF is common,
particularly for older patients and patients with heart failure.108 The adverse health
outcomes of undiagnosed AF include stroke and rate-related cardiomyopathy, and
patients with significant comorbidities and increased mortality more often have AF.109,
110, 111

As a risk factor, AF is associated with mortality in patients with evidence of

organic heart disease or systemic disorders. ECG monitoring 72 hours post-stroke112, 113
or for longer periods114, 115 enhances the diagnosis of silent AF. In older patient
populations (over 75 years of age), short-term ECG on a daily basis increases detection
of AF.116 It is unclear, however, whether early diagnosis changes management strategies
for AF patients and more research is warranted in this direction.

2.10 Drug Therapies After the Diagnosis of Atrial Fibrillation
Once the clinical significance of arrhythmia is determined, pharmacological
treatment of rate versus rhythm control is based on symptoms Acute cardioversion is
safe if the onset of AF is known to have been within 48 hours. Otherwise, one-month
anticoagulation therapy followed by cardioversion or trans-esophageal echocardiogram
(TEE) is required. The decision of initiating anticoagulation is dependent on the
CHADS score and whether cardioversion is to be attempted. A patient presented to the
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emergency department due to AF could be cardioverted electrically or with medications
if the onset of AF is known to have been less than 48 hours. In cases of new onset AF,
heart rate and rhythm can be controlled with anti-arrhythmic drugs as the first course of
action.117 Anti-arrhythmic drugs are prescribed for most patients with no need of
immediate cardioversion.117 Digoxin slows down ventricular heart rate but due to its
slow onset, it is less effective in patients with high levels of adrenalin.118, 119
In an emergency department setting, beta-blockers and calcium-channel
blockers can be administered intravenously120 as – irrespective of the patient’s
sympathetic tone – they initiate a much faster response. These drugs are also synergetic
with digoxin.121 However, they are very short-acting and must be followed by oral
administration if they work and are tolerated. In a clinic, oral forms of calcium-channel
blockers and beta-blockers are prescribed for newly diagnosed patients.
When adequately high doses are used at the onset of AF, anti-arrhythmic drugs
are generally effective in converting AF to normal sinus rhythm.122 However, the
majority of these patients come back to sinus rhythm spontaneously within a 24-hour
period of AF onset.123
Anticoagulant therapy is prescribed when the onset of AF cannot be accurately
determined in an emergency-department patient with the CHADS score of 0 .117
According to the Canadian Cardiovascular Society’s (CCS) Atrial Fibrillation
Guidelines (2010, 2012, 22014, and 2016)124, anticoagulant therapy is prescribed
regardless in patients with the CHADS score of more than 0 or age 65 or over even
when the time of onset is known. Early anticoagulant therapy is key as patients with
suspected AF are prone to blood clotting which can potentially lead to stroke.125, 126 The
risk of clot formation among older AF patient populations (80-89 years of age) that do
not receive anticoagulants can be particularly high and reach the value of 23.5%.127 To
prevent stroke for the current and future episodes and regardless of the time of onset, the
patient receives anticoagulant therapy.
The choice of a specific anticoagulant drug is dependent on the type of AF,
presence of comorbidities, patient’s adherence to the treatment plan as well as potential
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drug interactions.125 Medication compliance is of particular importance as a missed dose
increases the risk of thrombosis.128

2.11 Indications for Referral of Patients with Suspected Atrial Fibrillation
Referral pathways in AF are dependent on the type of AF and clinical
manifestation of the disease (Table 1). For a small group of haemodynamically
compromised patients at the onset of AF for less than 48 hours, the decision on
immediate hospitalization is driven by the patient’s clinical presentation.These patients
are referred for cardioversion within a 48-hour time-frame. The time window is key as
the patients may be cardioverted without the subsequent need of anticoagulation.
The referral pathway is tailored to individual needs of a patient and referral to a
specialist is usually required. Due to high inter- and intra-individual diversity in clinical
manifestation, it is difficult to define a typical case scenario for every type of AF. For
instance, a patient with persistent AF is usually referred for elective cardioversion and
for specialist advice to establish pharmacotherapy.29 Pharmacotherapy is also integrated
in patient care for those diagnosed with permanent AF. However, not all AF patients are
in need for pharmacotherapy and not everybody requiring pharmacotherapy will benefit
from specialist advice.29
Davis et al.29 distinguished the following most common reasons for referrals: 1)
failed medical treatment; 2) specific electrophysiological problems such as focal or
slow, symptomatic AF or Wolff-Parkinson-White syndrome; and 3) lone AF.
Due to its ambiguous and transient symptomatology or absence of such, the disease
of AF is difficult to diagnose. In addition, there is a broad heterogeneity in precipitants of
AF and diagnostic approaches. As a result, patients experience protracted assessment time.
This adds to emotional distress and significantly disrupts their daily living as well as delays
the start of evidence-based disease management.
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Table 1: Indications for Referral of Patients with Suspected Atrial Fibrillation:2

Type of Referral

Indications for Referral
•

Immediate / emergency referral

Early referral

haemodynamic compromise at the onset of atrial
fibrillation

•

atrial fibrillation for < 48 hours

•

onset of atrial fibrillation within 48 hours

•

patients with symptomatic atrial fibrillation

•

paroxysmal atrial fibrillation

•

persistent atrial fibrillation for possible
cardioversion

•
Elective referral

persistent or permanent atrial fibrillation for
advice on pharmacotherapy

•

failure of medical treatment

•

Wolff-Parkinson-White syndrome

•

lone atrial fibrillation

•

focal or slow symptomatic atrial fibrillation, which
may benefit from pacing

2

Davis M, Rodgers S, Rudolf M, Hughes M, Lip GYH. Patient care pathway, implementation
and audit criteria for patients with atrial fibrillation. Heart. 2007;93(1):48-52.
doi:10.1136/hrt.2006.099937
25

2.12 Patient-Centered Care and Lived Experience of Atrial Fibrillation
There is a growing tendency to give equal considerations both to clinical practice
perspective and to patients’ experiences, feelings, fears and expectations.129, 130, 131 At the
core of the rhetoric around healthcare reforms is the philosophy and practice of patientcentered care. Governmental agencies in Great Britain (National Health Service 2005),132
in the USA (US Department of Health and Human Services 2008)133 and in Australia
(Australian Commission on Safety and Quality in Healthcare 2012)134 along with the
World Health Organization135 and multiple health policy and patient-advocating
organizations around the world136, 137, 138 recognize the importance of prioritizing
individual patient’s needs in medical care delivery.
The first mention of patient-centered care was by Enid Balint in 1969139 who
juxtaposed “illness-oriented medicine” to a different way of medical thinking also known
as “patient-centered medicine”. In addition to establishing a medical diagnosis, the doctor
needs to consider the patient in one’s wholeness in order to be able to form “an overall
diagnosis”139. In Balint’s words, this two-fold task makes the doctor a general practitioner
for some patients and “a minor psychotherapist” to others. It was when “the problem of
the split doctor” was brought up for discussion. The question was whether such split was
aimed at as it might have changed the whole medical approach of the general practitioners.
Furthermore, doing “psychotherapy” with some patients would lead to the evolvement of
new skills – both as psychotherapists and as detective inspectors. Enid Balint was the first
researcher to challenge the traditional, taken-for-granted emphasis on the doctor’s
perspective rather than on what the patient “tries to get from the doctor”139.
The full publication of the patient-centred clinical method appropriate for family
medicine was by Levenstein et al.140 in 1986. In operational terms, a rigorous patientcentred method that is applicable to any family medicine situation, answers the question,
“What is the minimum that can be expected of any family physician at any patient
visit?”140 The authors’ firm belief140 is that it is essential for family medicine to develop
such a method.
Interestingly, in family medicine, a clear-cut diagnosis marks a failure, indicating
missed opportunities for disease prevention. When the patient presents cues of unwellness
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and the physician observes signs of the abnormality, the principle of an objective standard
does not work. It is important to assess the patient in relation to one’s own norms rather
than by an objective standard140.
For the patient-centredness to be effectively integrated into the disease
management which is “the quintessence of family medicine”141, the doctor needs to
understand both the patient and the disease. Levenstein et al. stress that this two-fold
purpose can only be achieved by including the process of differential diagnosis. At the
same time, the physician needs to know individual life circumstances of the patient, his or
her expectations, feelings and fears. Patient-physician interactions are best described in
terms of the patient’s and physician’s agendas140. As the patient-centered method relates to
the patient’s agenda, the physician sees the illness through the patient’s eyes by trying to
enter the patient’s world. Simultaneously, the doctor applies his disease-centered agenda
by bringing the patient’s problems into his clinical world of pathologies and diagnoses.
According to Levenstein et al140, there is no risk of invading a patient’s privacy in
this method if the doctor does not play the role of a detective inspector. Instead of probing,
the physician poses open-ended questions for the patient to express one’s own feelings,
expectations and fears. Through such an expression, the doctor gets the context of the
illness that may be crucial to understanding of the whole illness.
The concept of patient-centered care was further developed by the Picker Institute
in 1988142 and the existing scientific paradigm has already accumulated sufficient
evidence of benefits of patient-centered care.129 It can improve patient-important
outcomes,143, 144, 145, 146, 147 on the one hand, and reduce the workload and healthcare
expenditures,148149 on the other hand, by avoiding services that patients may neither want
nor need. From a legal standpoint, fewer malpractice lawsuits will occur150, 151 as personcentered care increases patient satisfaction.152 Lastly, patient-centered care has ethical
value of its own as it treats patients as persons with significance.153
While there is no singular, universally accepted definition of person-centered
practice, various health care groups tend to focus on its different aspects. This happens at
all the levels – from an individual encounter level, through various management stages to
policy activities.130 Being reflective of their professional interests and roles,130 different
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stakeholders interpret patient-centered care in their specific ways. In order to
operationalize this concept at the patient care level, it is key to explore the lived
experience of patients. Without mapping the patients’ journey through their interactions
with the health care system and across its organizational sectors, it is impossible to
meaningfully apply the concept of patient-centered care to individual patients.
Capturing patients’ experiences from the symptom onset to the definitive diagnosis
of AF is needed not only for the sake of early management from the doctor’s perspective,
but also for fear and uncertainty reduction, from the patient’s perspective. Each patient
journey can be slightly or totally different from what physicians anticipate it to be. A
standard case scenario would be the one of an emergency admission, with the arrhythmia
documented on ECG and a clinical diagnosis obtained.
A more typical experience, however, is characterized by delays in obtaining a
confirmed diagnosis.154 The delays are attributable to transient episodes of AF that are
difficult to “catch” on physical examination or to confirm by ECG. Shortness of breath,
palpitations and loss of energy are generic symptoms with no objective explanation154 that
are often interpreted by primary care physicians as insignificant and caused by stress.155
Symptom vagueness and arrhythmic elusiveness significantly defy diagnosis, making
some patients go to great lengths in validating their disease experience.154 As a result,
patients perceive themselves to be a “bother” that is either dismissed or not believed.156
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CHAPTER THREE – METHODS
3.1 Objectives
The objectives of this research were: 1) to characterize an AF episode of illness in
terms of the number of physician visits, episode length, medications prescribed, diagnostic
investigations ordered, and referrals made in a sample of Canadian family practice
patients; and 2) to compare the findings with the control group of patients living with
other chronic conditions by defining a magnitude of effect.
Objective One: to characterize an AF episode of illness in a sample of Canadian
family practice patients.
Question 1:
What is the mean and median number of physician visits in an AF episode of
illness?
Question 2:
What is the mean and median length (in months) of an AF episode of illness?
Question 3:
a) How many medications are prescribed during an AF episode of illness?
b) What medications are prescribed during an AF episode of illness?
Question 4:
a) How many diagnostic investigations are ordered during an AF episode of
illness?
b) What diagnostic investigations are ordered during an AF episode of illness?
Question 5:
a) How many referrals are made during an AF episode of illness?
b) What referrals are made during an AF episode of illness?
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Objective Two: to explore the differences between the study group and the control
group in terms of the number of physician visits, episode length, medications prescribed,
diagnostic investigations ordered, and referrals made as well as to measure an effect size.

3.2 The Deliver Primary Health Care Information (DELPHI) Database as
Source of Data
De-identified, high-quality data for a 10-year period (2005 – 2015) from 23
general practices in 10 primary care urban and rural practices from southwestern Ontario
were extracted from the DELPHI (Deliver Primary Healthcare Information) database and
further analyzed for the two objectives specified above.
The DELPHI Project is an ongoing project with the starting date of 2003. The
overarching goals of the project were:157 1) to facilitate information-sharing in
interdisciplinary primary healthcare by developing an EMR system; and 2) to define,
evaluate and improve the quality of primary health care.
Three types of structured data – symptoms, diseases and interventions - are coded
in the DELPHI database which is similar to an analogous albeit larger database in the
United Kingdom called the General Practice Research Database158. Twenty-three general
practitioners in ten primary care urban and rural practices from southwestern Ontario were
recruited into the DELPHI project. The constructed DELPHI database covers a wide
geographic area of Ontario, stretching to Windsor in the south, to Kincardine in the north,
to Brantford in the east and encompasses the London area. According to the DELPHI
developers, 157 sex and age distribution of the participating physicians represents Ontario
physicians as a whole, although the DELPHI sample of the participating physicians is less
urban. Age and sex distribution of the patients also largely resembles the Canadian general
population.
Data extraction from each practice occurs quarterly. The extracted data include the
billing code, family history, problem lists, interventions, medications, referrals, allergies,
laboratory tests, immunizations, investigations and physical examinations for each patient.
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On a random sample of patients with International Classification of Primary Care
(ICPC)-coded data (please see Section 3.3, below), the following additional data
components are extracted157: 1) up to five reasons for encounter (RFE) per visit coded
within the vocabulary available in ICPC (codes 1-20 for each chapter); 2) up to five
diagnoses per visit, and 3) non-chronic disease tracking within the framework of episodes
of care.
Each subsequent data extract is longer in its time-period than the previous extract
because the longer period includes the time of both the previous and the new extract. In
other words, the DELPHI database is re-created with successive cumulative extracts of
electronic medical records each quarter of the year. For instance, at Extract 1 (at the very
first data extraction since the launch of the DELPHI database), three months of data were
extracted; at Extract 2, six months of data were collected (three previous months + three
new months) and at Extract 3, nine months of electronic medical records were extracted
(six previous months + three new months) and so on. The pooled database that is being
refreshed on an ongoing basis, is referred to as the DELPHI database.
A unique number is assigned to each patient record. The patient’s name, address
and telephone number are not retrieved from the general practitioner’s office157. The only
personal identifiers collected are partial date of birth, partial postal code and sex/gender157.
Repeated data extraction is performed in such a manner that patients’ identification is not
required. Consequently, it is impossible to identify either a participating physician, or a
patient. Moreover, access to the database is restricted to personnel involved in DELPHI
research projects and only after they have signed confidentiality agreements.

3.3 The International Classification of Primary Care (ICPC)
The International Classification of Primary Care (ICPC) is a classification system
that was developed to categorize medical concepts into classes on the basis of their
relevance for primary care159, 45 The basic structure of an encounter within an episode of
illness distinguishes reasons for encounter, symptoms, complaints, diagnoses and
diagnostic and therapeutic interventions160.
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ICPC conversion structure with the International Classification of Diseases (ICD10) allows high specificity that is necessary in patient care161. For the use of expert
systems and for retrieval purposes, ICPC structures computer-based patient records into
the episode-oriented database. And a large nomenclature such as ICD-10 ensures the
highest possible level of specificity of the individual diagnostic labels. Consequently, on
the level of individual patients’ problem list, the complete conversion of ICPC and ICD10 ensures an optimal description of a patient’s clinical problems161.
The twenty-two chapters of ICD-10 include blocks corresponding to different body
systems: for instance, Chapter X corresponds to the diseases of the respiratory system
whereas Chapter XV encompasses pregnancy, childbirth and the puerperium and so on.
With its three core modes – a reason for encounter classification, a diagnostic
classification and a process classification, - the ICPC is used as an instrument for
identification and analysis of primary care elements. In application to this research, the
ICPC allows to move to an episode-oriented epidemiology159, when transitions (changes)
between encounters in an episode of care can be explored.
To include the ICPC aspect in the DELPHI project, the selected electronic health
record (EHR) company modified the existing EHR. As a result of the ICPC-related
modifications, the participating physicians needed to enter additional information that was
outside of their routine recording in the EHR. That was why the DELPHI personnel first
familiarized the health care providers with the core EHR functions162: the participating
sites received training in the entry of clinical data, billing and scheduling. Furthermore,
prior to the ICPC inclusion, the EHR was implemented for at least one year162.
Once the participants became proficient in their daily use of EHR, they were
introduced to the research specific data modifications162. The DELPHI personnel provided
specific examples to the participating sites to reinforce the importance of entering as much
as possible in the corresponding fields in the database. For instance, the results of the
physical examination performed in the office are to be entered into the “physical signs”
module rather than as narrative text in the notes field.
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To assess the degree to which all the EHR components were used for entering
appropriate data, audits were run. The identified weaknesses informed further, more
specific training that was offered either by the DELPHI staff or by the EHR company. For
the purpose of collecting reliable research data, only the health care providers (and not the
administrative staff)162 were asked to identify the relevant ICPC codes.
To further ensure data reliability, a three-phase ICPC training process was
implemented162.
At the first phase, the trainer reviewed ICPC-related theory with up to six
participants and provided multiple examples over a period of 1.5 hours. For future
reference, the participants received a laminated colour-coded list of ICPC code names, a
thirty-page ICPC manual, and a bound list of ICPC codes with descriptive details.
At Phase Two, fifteen previously developed clinical vignettes were distributed to
the participating sites with a request to identify ICPC codes that are relevant – in regards
to diagnosis and reason for encounter - to each case. Base on the results, inter-rater
reliability was assessed. Another set of fifteen vignettes was distributed among the
participants, after they got some experience in coding their actual encounters. Similarly,
these codes were used for the comparison of inter-rater (among the participants) as well
as intra-rater reliability (when compared to the initial results)162.
At the final 1.5-hour stage of training, the instructor demonstrated the correct use
of ICPC-related software that captures reason for encounter and diagnosis fields. Another
goal of the final stage of training was to ensure that the participants gained an
understanding of the episode of care structure within the EHR framework.
Approximately 10% of the DELPHI patient population was coded using ICPC. A
‘ramp-up’ method for coding ICPC data was implemented in order to simplify the process
for the physicians who were building up their confidence in using a new coding system. A
few patients from the physician’s list were randomly selected every day and then coded
using ICPC. For obtaining a longitudinal record, once a patient was selected, each
subsequent physician visit was ICPC-coded.

33

3.4 Episodes of Atrial Fibrillation Illness Defined Using ICPC-Coded Data
An episode of AF illness is defined as an inclusive number of days between the
first ICPC-coded encounter and the date of AF diagnosis. An episode length was
calculated by taking the difference in number of days between the starting point and the
end-point of an episode of illness, with the addition of one day to include the first and the
last day.
To identify patients with the diagnosis of AF, the International Classification of
Primary Care (ICPC, 2nd edition) code K78 (“atrial fibrillation/flutter”) was used. Since
this research was conducted within the framework of an episode of illness, there was a
need for accurate registration of physician visits in general practice. The focus was on the
reasons for encounter, the diagnoses and the interventions. These three components form
the core of an episode of illness and the ICPC provides detailed coding for them in EMR
data161.

3.5 Look-Back Period and Left-Censored Data
The choice of the type of a look-back period considerably impacts the number of
identified incident cases and depends on the research question and available data. As far as
the duration of a disease-free period is concerned, Czwikla et al.163 recommend using - if
data permit - a fixed-window look-back period of two years and more. A sufficiently long
disease-free period prior to diagnosis would allow one to distinguish incident cases from
recurrent and prevalent ones164 and prevent incidence overestimation.165 Of note, Schubert
et al.165 stress that three years of looking back can still lead to incidence overestimation.
Informed by the current research,166 the decision was made to use an all-available
rather than a fixed-window look-back period. A fixed-window look-back period has
limitations of its own and needs to be at least 1 year in length when used.167 Since there is
a defined study entry date (first diagnosis of AF), the use of all historically available
baseline information for each subject helps get an analytical sample of incident cases. All
the patients had available data for at least 6 months prior to diagnosis (the look-back
period) and differed in lead-up time before that period.
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It is often impossible to distinguish an absence of the condition from missing
data.166 Commonly and operationally, missing data indicate that the condition is not
present.168 However, if the diagnosis of AF has been established before the patients’
enrollment into the DELPHI database, it means that the data are left-censored. In this
instance, misclassification of incident cases163 and, thus, introduction of bias occurs. It is
particularly relevant to administrative data. We considered the possibility of left censoring
in the DELPHI database because the goal of DELPHI data collection was individual
patient care, not research.157 Only the cases with the documented diagnosis of AF were
included as it is considered to be a resilient case definition for incidence estimation.165

3.6 Definition of Independent Variables
3.6.1 Study Group
For the purpose of this research, the full sample of 69 patients with ICPC-coded
first-time diagnosis of AF (K78) comprises the study group.

3.6.2 Control Group
For Objective Two, an independent-samples t-test was performed to compare the
mean scores on the following dependent continuous variables – the number of physician
visits, the episode length, the number of medications prescribed, the number of diagnostic
investigations ordered, and the number of referrals made for two distinct groups of
patients – an AF group (the group of our primary interest) and a comparison group.
There are several steps involved in defining a comparison group which have been
informed by the review of literature on multimorbidity. Primarily, our decision has been
informed by Fortin, Almirall & Nicholson169. The comparison group is composed of nine
smaller groups of patients who are first ever diagnosed with one of the nine most
prevalent chronic conditions/categories of conditions in Canada. Each of the nine
mutually exclusive groups has more than 100 patients. These chronic
conditions/categories of conditions169 include hypertension; depression or anxiety;
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chronic musculoskeletal conditions causing pain or limitation; arthritis and/or rheumatoid
arthritis; osteoporosis; asthma, chronic obstructive pulmonary disease (COPD), or
chronic bronchitis; cardiovascular disease (angina, myocardial infarction, atrial
fibrillation, poor circulation in the lower limbs); heart failure (including valve problems
or replacement); and stroke and transient ischemic attack. For the purpose of comparison,
a group of patients from firstly diagnosed AF are excluded.
The pre-defined criteria that initially informed the selection of chronic conditions
and that are presented in the above mentioned article are coherent with our overarching
goal of exploring an AF patient journey in the primary care setting. They are:169 1)
relevance to a primary care setting; 2) impact on patients; 3) high prevalence in primary
care; and 4) high prevalence of occurrence in the existing body of literature. Grouping
related conditions under one category to be more flexible and inclusive of them is another
reason why we have adopted this approach for creating our comparison group. It also
allows comparability among studies that use the same criteria of creating comparison
groups or rely on the same measuring tool of comorbidity.
The first visit day and the day of diagnosis are used to calculate an episode length
and, subsequently, the number of physician visits, medications prescribed, diagnostic
investigations ordered, and referrals made within an episode of illness.
The 90-day lag period after the date of diagnosis is used for the number of
referrals and diagnostic investigations.

3.7 Definition of Dependent Variables
Five dependent variables were created: the number of physician visits, the episode
length, the medications, the diagnostic investigations, and the referrals. The number of
physician visits variable was coded using ICPC diagnostic codes within the pre-defined
framework of an episode of illness. Except for the ICPC component of the electronic
medical records, longitudinal records of patients’ medications, diagnostic investigations
and referrals were used to construct medications, diagnostic investigations, and referrals
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variables. To meet the first objective of the research, the descriptive statistics for the five
dependent variables are provided.

3.7.1 Number of Physician Visits
The number of physician visits is a count variable that is defined as the number of
in-office physician visits within the framework of an AF episode of illness. In the study
group, there were no patients with a one-visit episode of illness. The minimum number of
physician visits was 2 visits per an episode of illness and three of the patients were
fortunate to be diagnosed within a two-visit time period.

3.7.2 Episode Length
The episode length is a count variable that is defined as an inclusive number of
days between the first ICPC-coded physician visit and the physician visit during which
the diagnosis of AF was confirmed.
There was not a single one-day episode length. This variable was calculated by
getting the time difference between the date of diagnosis and the date of the first ICPCcoded physician visit within the framework of an episode of illness for each of the 69
participating patients. Consequently, 69 episodes of illness were defined in 69 patients,
with each of them having their varying episode length.

3.7.3 Medication
The medication variable is defined as the number and type of AF-specific
medications prescribed during the episode of illness. For Objective One (to characterize
an AF episode of illness for in a Canadian primary care setting), medication is defined as
a count variable. The choice of the two drug groups is based on the conducted review of
current treatment strategies of AF117. If promptly administered and at an adequately high
dosage, antiarrhythmic drugs are effectively used to convert AF to normal sinus
37

rhythm170. To prevent blood clot formation in the atria, anticoagulant therapy is
essential126.
This variable captured the AF-specific medication prescriptions that were
recorded in the electronic medical records (EMRs) during physician visits within an
episode of illness.
To confirm relevance of identified medications to an AF episode of illness, each
drug title was queried on HealthyOntario.com. It is a Canadian government-sponsored
health information site that promotes greater individual responsibility for well-being by
addressing everyday health concerns in layman’s terms171. As far as medication is
concerned, HealthyOntario.com is a helpful resource of ensuring medication review and
safety in order to decrease rates of “near misses”172. A “near miss” is an event in
medicine that had the potential of resulting in harm to the patient but did not occur
because of the timely intervention by the patient, the physician or the family member, or
due to good fortune. “Near misses” are also known as "good catches" or “close calls”.

3.7.4 Diagnostic Investigation
The diagnostic investigation variable is defined as the number and type of
diagnostic investigations performed within an episode of illness. To meet Objective One
(to characterize an AF episode of illness in Canadian family practice), this variable is
labelled as a count variable.
By its major types, the diagnostic investigation variable has the following
categories that are initiated in a primary care setting29: clinical assessment, basic blood
tests (including thyroid function tests), chest X-rays and an electrocardiogram (ECG). We
expect to see ECG as a diagnostic test for many patients diagnosed with AF as, according
to current guidelines for the diagnosis of AF, confirmation of the arrhythmia through
ECG, telemetry, or portable heart rhythm recorder is essential29. However, the best
practice guidelines may not necessarily be followed as was revealed by a study
describing the management of prevalent cases of atrial fibrillation in two UK practices.
The authors reported a suboptimal use of standard diagnostic investigations, with only
38

18% of the patients receiving an ECG close to the date of their first diagnosis173. More
specialized diagnostic investigations such as electrophysiological studies may require a
referral to a secondary care clinical setting. Some general practitioners, however, have
open-access echocardiography in their offices, which should significantly expedite
assessment of patients for functional and structural heart disease29.

3.7.5 Rationale for Lag Period in Definition of Diagnostic Investigation
In the sample of 69 patients, there were instances when it was impossible to link a
diagnostic investigation to the physician visit during which it was ordered. Missed
appointment dates is another challenge that makes it impossible to associate a specific
diagnostic investigation with a specific physician visit. Moreover, the date of record
creating could denote several options ˗ the date of the investigation being ordered, the
date of the appointment being booked, or the date of inputting diagnostic results into the
EMRs. Although the date of record creating did not have any missed value, it still lacked
interpretative power. In order to resolve this issue, a lag period of 90 days was
incorporated into the variable definition.

3.7.6 Referral
The referral variable is defined as the number and type of referrals made during
the episode of illness. To meet Objective One, the referral variable is defined as a count
variable.
A referral was included in the episode of illness if the date of the referral was
recorded between the starting and end-points of the episode of illness plus a 90-day lag
period. Both AF-related and non-specific referrals were included into the episode of
illness.
In order to define AF-specific referrals, additional components of the EMR were
explored to determine the type of information recorded in the EMR and the mode of its
categorization. A referral record was a separate dataset in the EMR extract and provided
39

the following information: a type, purpose, an appointment date of referral (with the
name of the referred physician), a date of record creation, and an encounter number to
bind the referral with the schedule of physician visits.
The referral dataset included all the referrals recorded for the patient, regardless
of the underlying reasons for the referrals. Both AF-specific and non-specific referrals
recorded within the episode of illness were included in the subsequent analyses.

3.7.7 Rationale for Lag Period in Definition of Referral
The same rationale for a 90-day lag period applies in definition of both the
referral and diagnostic investigation variables.

3.8 Data Analysis Objective One: Characteristics of an Atrial Fibrillation
Episode of Illness
IBM SPSS Statistics 25 software was used for statistical analyses conducted on
the entire sample of 69 patients with firstly diagnosed AF. Correspondently, 69 complete
episodes of AF illness were identified for subsequent analysis.
To minimize measurement biases in statistical analyses, each variable in the data
file was checked for errors. To do so, the frequencies for all the variables were inspected.
It allowed to ensure that there were no values falling outside the range of possible values
for each specified variable.

3.9 Data Analysis Objective Two: Comparison of Study Group and Control
Group.
3.9.1 An Independent-Samples T-Test
As we would like to compare the mean scores of the five continuous dependent
variables in the study group with the mean values from the control group, an
independent-samples t-test is an appropriate statistic.
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3.9.2 Underlying Assumptions for an Independent-Samples T-Test174
Level of Measurement: It is assumed that each dependent variable uses a
continuous scale instead of discrete categories. At the initial stage of the research
planning, a decision was made to give a preferential choice to continuous dependent
variables. It gave us a wider range of techniques to choose from for data analysis.
Random Sampling: The scores are assumed to be obtained from a random
population sample.
Independence of Observations: The observations are assumed to be statistically
independent of one another, i. e., not influenced by any other measurement or
observation.
Normal Distribution: The populations from which the samples are taken are
assumed to be normally distributed. This is often not the case in real-life research as
scores on dependent variables can be not normally distributed. However, with a relatively
large sample size (more than 30), approximately normal distributions are sufficient.
Moreover, most statistical techniques are robust to this assumption.
Homogeneity of Variance: Samples are assumed to be obtained from populations
of equal variances. In other words, the variability of scores in each group is expected to
be similar.

3.9.3 Effect Size Statistics
Following the guidelines of the fifth edition of the American Psychological
Association (APA), effects sizes are reported for Objective Two: “it is almost always
necessary to include some index of effect size or strength of relationship in your results
section, for the reader to fully understand the importance of your findings”175. Similarly,
Snyder and Lawson176 emphasize that it is impossible to predict an effect size based
entirely on statistically significant results. In unison with them, Thompson177 and
Volker178 believe the effect size to be critical information that cannot be assessed by
considering only a P-value.
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Being a function of both an effect and sample size, a small P-value can relate to
any magnitude of effect179. With a large sample size, the likelihood of getting a
statistically significant difference is increased. However, a small P-value might not mean
a large effect size. Conversely, a modest study can generate a large effect, regardless of
its statistically insignificant findings that are the direct consequence of the small sample
size176, 179.
In the absence of previously reported effect sizes for the dependent variables of
interest in the literature (the number of physician visits, the episode length, the
medication prescribed, the diagnostic investigation ordered, and the referral made), a
decision was made to report several common effect size statistics and to compare the
results between them: Cohen’s d, eta-squared, Glass’ delta, and Hedge’s g. All the
measures of effect size are used to interpret the strength of association between the group
variable as an independent variable and each of the five dependent variables. Moreover,
reporting multiple effect sizes to address the same question improves the communication
of the results180.

3.9.4 Missing Data
There were no missing data for any of the variables included in the analysis.

3.9.5 Outlying Points
Since many statistical techniques are sensitive to outliers,181 it is essential to check
for cases with values significantly below or above the majority of other cases. This was
done by inspecting the residuals in the Residuals Statistics table.
Another statistic used for assessing the presence of outliers was the 5% trimmed
mean, when the software removed the top and bottom 5 per cent of the cases and
calculated a new mean value.181
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CHAPTER FOUR – RESULTS
4.1 Sample Description
The sample consists of 69 complete AF episodes of illness extracted from the
ICPC-coded part of the DELPHI database over a four-year period, between October
2005 and September 2009. A summary of patient- and episode-level characteristics is
presented in Table 2. This table also contains information on the top five most common
chronic conditions.
From the output generated by IBM SPSS, by biological sex, there are 35 females
(50.7%) and 34 males (49.3%), giving a total of 69 patients. By age, the patients range
between 50 and 95 years old at the time of their diagnosis, with a mean of 75.83 and a
standard deviation of 10.68. Only 5% of the patients are younger than 55 years of age
and another 5% are above the age of 90. 25% of them are not older than 71 years of age
at the time of diagnosis. Another 25% of the patients are older than 83 years of age.
Out of the ten practices participating in the DELPHI project and contributing their
patient-level data to the DELPHI database, only seven practices had ICPC-coded data
on first-time-diagnosed AF patients. 28 patients (40.6%) were seen in one rural primary
care practice whereas 41 patients (59.4%) visited six urban practices, thus
demonstrating a higher clustering of cases in the urban setting.
Three practices (one rural and two urban) accounted for 88.4% of all the cases. Of
the 88.4%, slightly more cases (by 7.2%) were diagnosed in the two urban practices
than in the one rural practice. There were 33 urban cases (47.8%) compared to 28 cases
(40.6%) in the rural setting.
When further analyzed by the doctor’s code, 40.6% of the 69-patient sample (28
cases) were diagnosed by two doctors in the single rural practice that is presented in the
sample. Surprisingly, one doctor in this particular practice diagnosed AF in 20 patients,
thus accounting for 29.0% of all the cases in the sample.
The larger of the two urban practices added another 25 cases (36.2%) to the
sample. There were five diagnosticians in total in that practice, with three of them
having identified one new case each (4.2%) and one of them having established the
diagnosis of AF in two patients (2.9%). Similarly, there was a doctor in the practice
43

who identified 20 incident cases, thus contributing another 29.0% of patients to the
final sample.
The much smaller urban practice – in terms of its contribution of cases – had only
one doctor who identified 8 new cases of AF (11.6% of the sample).
Only 27.5 % (19 cases) do not have any comorbidities, i.e., they have a single
diagnosis of AF; the mean number of diagnoses is 6.74, with a standard deviation of
7.41.
As the literature considers the reason for encounter to be a practical source of
patient information161, we have decided to include it for a more detailed description of
the sample. Furthermore, ICPC contains over 200 complaints and symptoms serving the
categorization of both clinical findings and reasons for encounter161.
The reasons for encounter are registered in the ICPC-coded portion of the
DELPHI database in the form of ICPC codes. The five most prevalent reasons for
encounter are 1) blood test; 2) weakness/tiredness general; 3)
medication/prescription/renewal/injection; 4) hypertension uncomplicated; and 5)
medical examination.
There are two broad classes of reasons for encounter: 1) procedural or diagnostic
and 2) therapeutic interventions. It is important to distinguish between the two of them
as a specific type plays a crucial role in explaining the differences in the intervention
distribution within an episode framework49. It is also the case that these two classes
may be mixed. They are not mutually exclusive in that patients may come requesting a
procedure or in need of a diagnosis, but also undergo an intervention.
Procedural reasons for encounter include, for instance, patient’s requests for
interventions, a referral to a specialty outpatient clinic/tertiary care hospital, an X-ray of
different body parts (as the most common type of diagnostic investigation), a
medication prescription or renewal, etc. Given the proportion of the patients studied
who had multiple chronic conditions, the most common procedural reason for
encounter was medication renewal.
Out of the total 361reasons for encounter in the sample, 298 (82.5%) were
procedural in nature. This finding has important implications for clinical care, as
patients are no longer seen as passive recipients of medical services but rather active
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participants in diagnosis and treatment. They are able to identify their own needs and
request the services that they believe to be beneficial to their health and well-being. In
other words, patients shape the content of primary care45. As a result, primary care
physicians – those in general practice, pediatrics, family and internal medicine182 –
although performing a gatekeeper function, are inclined to satisfy their patients’
requests183. The high number of procedural reasons for encounter at the first date of AF
diagnosis is highly suggestive of this tendency. Less than 20 per cent of the reasons for
encounter are initiated due to patients’ symptoms and complaints at the date of AF
diagnosis. This means that for the overwhelming majority of AF patients in the sample,
the disease of AF does not have clinical manifestation that could be self-reported in the
form of symptoms.
Comorbidity is defined as “a distinct additional clinical entity”184.In terms of the
presence of comorbidities, approximately 20 per cent of the patients did not have any
other comorbidities: AF was a first chronic condition they have ever been diagnosed
with. Forty per cent of the patients, however, had been diagnosed with 2 to 3 chronic
conditions. A relatively large number of patients (16%) were diagnosed with five or
more chronic conditions.
The five most prevalent comorbidities account for 72.4% of all the comorbidities
recorded in the sample. The five less common chronic conditions represent 16.8% of
the total number of comorbidities. As expected, the top two of these – cardiovascular
disease and hypertension – are cardiac related. The other three from the top five chronic
conditions ˗ arthritis, chronic musculoskeletal and diabetes - are likely to be age-related
as the mean age at diagnosis is 75.8 years of age. The five less prevalent chronic
conditions accounted only for 16.8% of the total number of chronic conditions.
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Table 2: Description of Sample

Characteristics

Central Tendency and
Dispersion/Type

Frequency (%)

Patient-Level
Characteristics
Age at Diagnosis (years)

Mean
Std. Deviation
Percentile 5
Percentile 25
Percentile 50

75.8 years
10.7 years
55 years
71 years
77 years

Minimum
Maximum
Range

50 years
95 years
45 years

50-60 years
61-70 years
71-80 years
81-90 years
91-95 years

9 (13.0%)
8 (11.6%)
27 (39.2%)
23 (33.3%)
2 (2.9%)

Male
Female

34 (49.3%)
35 (50.7%)

Practice Type

Urban
Rural

41 (59.4%)
28 (40.6%)

Number of Practices

Urban
Rural

6
1

Sex

Episode-Level
Characteristics
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Table 2: Description of Sample Continued
Characteristics

Central Tendency and Dispersion/Type

Frequency (%)3

Episode-Level
Characteristics
Number of Cases by
Doctor’s Code

Practice 004-14
Practice 004-2
Practice 009-1
Practice 009-2
Practice 009-3
Practice 009-4
Practice 009-5
Practice 010-1

Distribution of
Reasons for Encounter
at First Date of
Diagnosis

0 reason for encounter
1 reason for encounter
2 reasons for encounter
4-6 reasons for encounter
8-10 reasons for encounter
13-18 reasons for encounter
Total # of reasons for encounter

8 (11.6%)
20 (29.0%)
1 (1.4%)
2 (2.9%)
1 (1.4%)
1 (1.4%)
1 (1.4%)
8 (11.6%)

5.91
5.43
0
18
18
1
4
9

Mean
Std. Deviation
Minimum
Maximum
Range
Percentile 25
Percentile 50
Percentile 75

Description of Top 6
Reasons for Encounter
at First Date of
Diagnosis

34 (9.4%)
75 (20.8%)
35 (9.7%)
89 (24.6%)
73 (20.2%)
55 (15.2%)
361

Medication/prescription/renewal/injection
Blood test
Weakness/tiredness general
Hypertension uncomplicated
Medical examination/health evaluation
Preventive immunization/medication

28 (7.7%)
13 (3.6%)
11 (3.0%)
10 (2.8%)
9 (2.5%)
9 (2.5%)

The percentage of “description” is the number of episodes of illness with a reason for encounter from the total
episode of illness sample. It may not add up to 100% as some episodes of illness have a few reasons for encounter
whereas others have none.
4
The first three digits indicate the practice number and the last digit refers to a doctor in that practice.
3
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Table 2: Description of Sample Continued
Characteristics

Central Tendency and Dispersion/Type

Frequency (%)5

Episode-Level
Characteristics
Reasons for Encounter
at First Date of
Diagnosis

Symptom-free (procedural)
Symptoms & complaints
Total # of reasons for encounter

Chronic Conditions

Mean
Std. Deviation
Minimum
Maximum
Range
Percentile 25
Percentile 50
Percentile 75

Distribution of
Chronic Conditions

1 chronic condition
2 chronic conditions
3 chronic conditions
4 chronic conditions
5 chronic conditions or more
Total # of chronic conditions

15 (7.2%)
40 (19.3%)
51 (24.6%)
24 (11.6%)
77 (37.3%)
207

1 chronic condition
2 chronic conditions
3 chronic conditions
4 chronic conditions
5 chronic conditions or more
Total # patients

15 (21.7%)
20 (29.0%)
17 (24.6%)
6 (8.7%)
11 (16.0%)
69

CVD
Hypertension
Arthritis
Chronic Musculoskeletal
Diabetes

83 (40.1%)
29 (14.0%)
15 (7.2%)
13 (6.3%)
10 (4.8%)

Description of Top 5
Chronic Conditions

298 (82.5%)
63 (17.5%)
361

4.34
2.59
1
11
10
2
3
6

5

The percentage of “description” is the number of episodes of illness with a chronic condition from the total episode of illness sample. It may not
add up to 100% as some episodes of illness have a few chronic conditions whereas others have none.
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Table 2: Description of Sample Continued

Characteristics

Central Tendency and Dispersion/Type

Frequency (%)

Episode-Level
Characteristics
5 Less Prevalent
Chronic Conditions

6
7

Asthma/COPD6/Bronchitis
Heart Failure
Depression/Anxiety
Hyperlipidemia7
Cancer

COPD chronic obstructive pulmonary disease
Hyperlipidemia – a high concentration of lipids or fats in the blood
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9 (4.3%)
9 (4.3%)
7 (3.4%)
5 (2.4%)
5 (2.4%)

4.2 Objective One: Characteristics of an Atrial Fibrillation Episode of Illness
To complete Objective One of the thesis, Table 3 summarizes important findings
that characterize an AF episode of illness in general practice. There was not a single onevisit AF episode of illness in the sample of 69 patients, i.e., none of the patients were
diagnosed with this chronic condition by the end of their first doctor’s appointment that
was also a first ever ICPC-coded visit in the DELPHI database. It took approximately 10
per cent of the patients up to 5 physician visits before AF diagnosis. In the middle of the
spectrum were another 35 per cent of the patients who paid between 11 and 20 visits to
their family doctors before receiving their diagnosis. A striking and somewhat
unexpected finding is that 37.7% of the patients had 26 visits or more after which an
established diagnosis of AF was shared with them.
As far as the episode length is concerned, none of the patients were diagnosed
with AF within an eight-month period and only 1 of 69 patients knew by the end of the
ninth month that he or she had this condition. Over 40 per cent of the patients got
diagnosed a year and a half later. Another 38 per cent of the patients received a diagnosis
of AF after 20 to 49 months. About 8% of the patients (6 out of 69 patients) (8.5%) got
diagnosed with AF after 50 months or more.
A substantial number of medications (with the mean of 21.1 and the standard
deviation of 12.8) was prescribed within all the episodes of illness. There was not a single
episode of illness in which no medication was prescribed. A small portion of patients
(7.2%) was prescribed a moderate number of medications (compared to the rest of the
sample), i. e., 1-5 medications. There was another 10 per cent of the patients who got
prescribed 21 medications and more. Diuretics (6.6%), anticoagulant medication (6.2%),
and beta-blockers (4.4%) were most commonly prescribed. The minimum number of
medications was 1 and the maximum number was 46, giving a wide range of 45
medications.
Different diagnostic investigations were ordered for about 52 per cent of the
patients. Consequently, approximately another half of the patients (47.8%) did not
undergo any diagnostic investigations. It is important to note that ECG as a cardiacspecific diagnostic tool comprises only 14.9% of the total number of investigations.
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Twenty five ECGs were done for 16 patients. It is also worth mentioning that 11 out of
25 ECGs were performed on two patients (7 and 4 ECGs, respectively) and the majority
of the “ECG patients” attended a single rural practice. So in the sub-sample of 36 patients
undergoing any type of diagnostic investigations, only 16 patients were prescribed ECG
as a cardiac-specific investigation. In other words, 44.4% (16/36) of those experiencing
diagnostic investigations of any sort, had ECGs performed throughout their journey to the
diagnosis of AF.
For our patient sample, the most commonly utilized type of investigation was an
X-ray of different body parts. Out of the patients that were sent for further diagnostic
investigations (i.e., half of the sample), 50 per cent had fewer than four investigations and
25 percent had more than eight diagnostic investigations.
For the total sample of 69 patients, there were 106 referrals, i.e., less than 2
referrals per each patient (106 referrals/69 patients = 1.5). Almost half of the patients
(46.4%) were not referred to any secondary/tertiary care service. So if we take only the
patients who did get referred to medical services outside their family physicians’ offices
(37 patients), we will get the proportion of 2.9 referrals for each referred patient: 106
referrals / 37 referred patients = 2.9 referrals for each referred patients.
By looking closely at the referral types, one can see that cardiology referrals make
only a small proportion of 5.7% of the total number of referrals. By going even further
into the data, one can find that the six referrals to the cardiologist were made for 5
patients attending the single participating rural practice that contributes 28 patients or
40.6% of the total sample size. There was no cardiac-specific referral made in any of the
six participating urban practices.
30 per cent of the patients had one referral within their episodes of illness. 10 per
cent had two referrals and another 10 per cent of the patients were referred three times
within the framework of an AF episode of illness. A very small proportion of patients
(4.3%) had a large number of referrals (over 13 referrals).
As far as the description of the referrals is concerned, cardiology referrals are at
the bottom of the list for the top six referrals and comprise only 5.7% of the total number
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of referrals. Internal medicine as the most common referral type (19.8% of the total
number of referrals) followed by referrals for orthopedic (11.3%) and vascular surgery
(10.4%). Among less common types of referrals that still make to the top-six list are
dermatology and neurology, with 10.4% and 4.7% of the total number of referrals,
respectively.
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Table 3: Episode of Illness Characteristics
Characteristics

Central Tendency &
Dispersion / Type

Number of Physician
Visits

2 visits
3 visits
4 visits
6 visits
7-15 visits
17-30 visits or more
31 visits or more
Total # of visits

Mean
Median
Std. Deviation
Minimum
Maximum
Range

0-5 visits
6-10 visits
11-15 visits
16-20 visits
21 visits or more
Total # of patients

Mean
Median
Std. Deviation
Minimum
Maximum
Range
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Frequency (%)

6 (0.4%)
4 (0.3%)
19 (1.3%)
14 (0.9%)
316 (21.2%)
440 (29.5%)
688 (46.1%)
1487

32.2
30
19
2
75
73

7 (10.2%)
11 (15.9%)
14 (20.3%)
11 (15.9%)
26 (37.7%)
69

20.8
16
15.7
3
52
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Table 3: Episode of Illness Characteristics Continued
Characteristics

Central Tendency &
Dispersion / Type

Episode Length (months) 1-8 months
9 months
10-19 months
20-29 months
30-39 months
40-49 months
50 or more months
Total # of patients
Mean
Median
Std. Deviation
Minimum
Maximum
Range

Distribution of
Medications

1 medication
2 medications
3 medications
4 medications
5-10 medications
11-15 medications
16-20 medications
21-46 medications
Total # of medications
Mean
Median
Std. Deviation
Minimum
Maximum
Range
1-5 medications
6-10 medications
11-15 medications
16-20 medications
21 medications and more
Total # of patients
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Frequency (%)

0 (0%)
1 (1.4%)
29 (41.9%)
13 (18.7%)
14 (20.1%)
6 (8.5%)
6 (8.5%)
69
25.9
22
13.7
9
56
47

1 (0.1%)
2 (0.1%)
10 (0.5%)
9 (0.5%)
378 (20.4%)
427 (23.1%)
324 (17.6%)
694 (37.7%)
1845
21.1
17
12.8
1
46
45
6 (7.2%)
30 (43.5%)
17 (24.6%)
9 (13.0%)
7 (10.1%)
69

Table 3: Episode of Illness Characteristics Continued
Characteristics
Central Tendency &
Frequency (%)8
Dispersion/ Type
Description of
Diuretics
123 (6.6%)
Medications
Anticoagulants
116 (6.2%)
Beta-blockers
80 (4.4%)
Statins
69 (3.7%)
Non-opioid pain relievers
69 (3.7%)
Anti-inflammatory
54 (3.0%)
Antiarrhythmic
45 (2.4%)
Hypertension
37 (2.1%)
Opioid pain relievers
28 (1.8%)
Vitamins
26 (1.7%)
Antidepressants
25 (1.4%)
Diabetes medication
24 (1.3%)
Medication for angina
24 (1.3%)
Thyroid replacement hormones
24 (1.3%)
Gastrointestinal
18 (1.0%)
Corticosteroids
16 (0.9%)
Distribution of
Investigations

0 investigation
1 investigation
2 investigations
3 investigations
4 investigations or more
Total # of investigations
Mean
Median
Std. Deviation
Minimum
Maximum
Range
0 investigation
1 investigation
2 investigations
3-6 investigations
7 investigations or more
Total # of patients

8

33 (19.6%)
10 (6.0%)
8 (4.8%)
24 (14.3%)
93 (55.4%)
168
4.0
3.99
0.00
0
12
0
33 (47.8%)
10 (14.5%)
4 (5.8%)
16 (23.2%)
6 (8.7%)
69

The percentage of “description” is the number of episodes of illness with a medication from the total episode of illness sample. It may not add
up to 100% as some episodes of illness have a few medications whereas others have none.
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Table 3: Episode of Illness Characteristics Continued
Characteristics

Central Tendency &
Dispersion / Type

Distribution of
Investigations

Percentile 25
Percentile 50
Percentile 75

Description of Top 6
Investigations

XR (different body parts)
ECG
US (different body parts)
XR (chest)
CT10 (different body parts)
Nuclear Medicine

Distribution of Referrals 1 referral
2 referrals
3 referrals
4 referrals
6 referrals or more
Total # of referrals

Description of Top 6
Referrals

Frequency (%)9

1.0
4.0
8.0
43 (25.8%)
25 (14.9%)
22 (13.2%)
19 (11.3%)
8 (4.8%)
4 (2.4%)

2.0 (1.9%)
14 (13.2%)
9.0 (8.5%)
12.0 (11.3%)
69.0 (65.1%)
106

0 referral
1 referral
2 referrals
3-6 referrals
13 referrals or more
Total # of patients

32 (46.4%)
21 (30.4%)
6 (8.7%)
7 (10.1%)
3 (4.3%)
69

Internal Medicine
Orthopedic Surgery
Vascular Surgery
Dermatology
Cardiology
Neurology

21 (19.8%)
12 (11.3%)
11 (10.4%)
11 (10.4%)
6 (5.7%)
5 (4.7%)

The percentage of “description” is the number of episodes of illness with a referral from the total episode of illness
sample. It may not add up to 100% as some episodes of illness have a few referrals whereas others have none.
10
CT computerized tomography (CT-scan)
9
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4.3 Objective Two: Comparison of Study Group and Control Group. An
Independent-Samples T-Test
A series of independent-samples t-tests were conducted to compare the mean
values for the number of physician visits, the episode length, the number of medications,
diagnostic investigations and referrals between the AF and comparison groups.
We first ran a Levene’s test for equality of variances to assess whether the
population variances for the groups were equal185. This test result also determined that the
t–value under no assumption of equal variances was the correct one to use for further
interpretation of the five dependent variables of interest.
The review conducted by Glass, Peckham, and Sanders in 1972186 defined an Fstatistic to be robust against heterogeneous variances when groups are equal in size.
Stevens185 goes further by stating that the robustness of the F-statistic is preserved with
approximately equal group sizes, i. e., the ratio of the largest sample to the smallest is not
more than 1.5. This rule of thumb demonstrates robustness again unequal population
variances only for two out of five dependent variables – for the number of physician
visits (1487/1287 = 1.2) and for the number of medications (1845/1327 = 1.4). For the
remaining three variables – the episode length, the number of diagnostic investigations
and referrals – the ratio values are much higher, thus demonstrating sharply unequal
sample sizes: 3.7 (1327/361), 7.9 (1327/168), and 12.5 (1327/106), respectively.
Since the level of significance for Levene’s test is P < .05, the observed variances
for the two groups are different. Therefore, the assumption of homogeneity of variance is
violated. It indicates that the two samples for the AF and the comparison groups are not
taken from populations of equal variances. As a result, the P-value from the first, “equal
variances assumed” row is not trustworthy: the two groups are substantially unequal in
size and the population variances are different.
IBM SPSS accounts for the homogeneity of variance violation by giving slightly
different results in the second row under “equal variances not assumed”. In fact, when
performing a standard independent-samples t-test, this software automatically runs a
Welch t-test statistic under the “equal variances not assumed” or second row.
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The Welch t-test, also known as the Unequal Variance t-test or Separate Variances
t-test is used here as an alternative statistic. Since the Welch t-test is robust to unequal
variances and unequal sample sizes simultaneously, its use is relevant in our case. The
null hypothesis it tests is that two means are equal even when the variances are
statistically significantly different from each other as well as when sample sizes are
unequal.
To ensure a higher level of robustness to unequal variances and unequal sample
sizes, the Brown-Forsythe test was also performed. It is arguably even more robust than
the Welch t-test187. The results of the Welch t-test and the Brown-Forsythe test are
presented in the table below: the independent-samples t-test under the 'equal variances
not assumed’ option is in fact the Welch t-test itself. For the five dependent variables of
interest, the Welch t-test and the Brown-Forsythe test yielded exactly the same results
within each dependent – group variable pair.
The results of independent-samples t-tests are presented below.
Since for all the dependent variables, the value of significance (Sig.) in Levene’s
test for the Equality of Variances is below the required cut-off of .05, we interpret an
alternative t-value generated by the software which is, in fact, the result of the Welch ttest. As previously mentioned, the Welch test compensates for unequal variances and, for
result interpretation, the t-value under the ‘equal variances not assumed’ option is
reported. This applies to the t-test results for all the dependent variables.
Number of Physician Visits: An independent samples t-test was conducted to
compare the number of physician visits for the AF and the comparison groups. There is a
highly statistically significant difference (t (2562.46) = 32.68, P (two-tailed) < .001) in
the number of physician visits between the two groups, with the mean value for the AF
group (M = 33.17, SD = 19.04) being over twice that of the comparison group (M =
13.58, SD = 12.19). Patients with undiagnosed AF visit their primary care physicians, on
average, 33 times before they obtain a firstly established diagnosis of AF. It usually takes
patients with other prevalent chronic conditions 2.5 times fewer visits (about 13 in total)
to visit their family doctor’s offices before their chronic condition is first diagnosed.
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The Number of Medications: In accordance with the results of the independentsamples t-test, the difference in the mean number of medications for the AF and the
comparison groups is highly statistically significant: t (3131.41) = 19.11, P < .001. The
mean number of different medication names for both groups indicate that AF patients
tend to have slightly over 50% more medications prescribed (M = 21.13, SD = 12.83),
when compared to patients with other chronic conditions (M = 13.27, SD = 10.31).
The Episode Length (Days to Diagnosis): The performed independent-samples ttest indicates that – in terms of the time-to-diagnosis (number of days) ˗ patients who are
first diagnosed with AF, wait, on average, for 2.8 years (when the number of days is
converted to the number of years: 1019.27 days are equal to 2.8 years). Their
counterparts from the control group, on the other hand, have their new diagnosis of a
chronic condition established in slightly less than a year and a half (560.17 days). The ttest findings of t (521.761) = 20.23 are highly statistically significant as the P-value is
less than .001. In a summary, there is a highly statistically significant difference in the
time-to-diagnosis for the AF group (M = 1019.27, SD = 391.78) and for the comparison
group (M = 560.17, SD = 345.16); t (521.761) = 20.23, P (two-tailed) < .001.
The Number of Investigations: Generally, patients with AF have more diagnostic
investigations ordered by their physicians compared to the numbers from the comparison
group. The mean value of 4.88 (standard deviation of 3.99) for the AF group are 50%
higher than the mean value of 3.28 (standard deviation of 3.72) for the comparison group.
As is the case with other, previously described dependent variables, this t-test also yields
a highly statistically significant result (t (205.319) = 4.92) as the two-tailed P-value of the
test is much lower than the required cut-off of .05 (P < .001).
The Number of Referrals: An independent samples t-test was performed to
compare the number of referrals made for the AF and the comparison groups. There is a
highly statistically significant difference (t (1326.000) = 4.90, P (two-tailed) < .001) in
the number of referrals made between the two groups, with the mean value of 1.0000 and
the standard deviation of 0.7713 for the AF group being, however, very close in its
numeric value to the mean of 0.7769 and the standard deviation of 1.65819 for the
comparison group.
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Table 4: Group Statistics for Independent-Samples T-Test
Characteristic

Group

N

Mean

Std. Deviation

Std. Error Mean
.

Physician Visits

Medications

Episode Length (Days to
Diagnosis)

Diagnostic Investigations

Referrals

AF

1487

33.1742

19.04291

49383

Comparison

1287

13.5835

12.18994

.33979

AF

1845

21.1301

12.82827

.29865

Comparison

1327

13.2683

10.30817

.28297

AF

361

1019.27

391.782

20.620

Comparison

1327

560.17

345.160

9.475

AF

168

4.8750

3.99429

.30817

Comparison

1327

3.2781

3.71723

.10204

AF

106

1.2347

.7713

.00103

Comparison

1327

.7769

1.65819

0.04552
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Table 5: Independent-Samples T-Test
Levene’s Test for
Equality of
T-Test for Equality of Means
Variances
Characteristic

Assumption

Equal variances
assumed
Physician
Visits

F

Sig.

t

df

Sig.
(2-tailed)

369.067

.000

31.709

2772

.000

19.59065

.61782

18.37921

20.80208

32.682

2562.461

.000

19.59065

.59944

18.41522

20.76608

18.448

3170

.000

7.86181

.42616

7.02624

8.69738

19.109

3131.407

.000

7.86181

.41142

7.05512

8.66849

21.748

1686

.000

459.100

21.110

417.695

500.505

20.231

521.761

.000

459.100

22.693

414.519

503.680

Equal variances
not assumed
Equal variances
assumed

122.153

.000

Mean
Sd. Error
Difference Difference

95% Confidence
Interval of the
Difference
Lower
Upper

Medications
Equal variances
not assumed
Equal variances
assumed
Episode
Length (Days
to Diagnosis)

Equal variances
not assumed

26.217

.000
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Table 5: Independent-Samples T-Test Continued

Levene’s Test for
Equality of
Variances
Characteristic

Diagnostic
Investigations
+ 90-Day Lag
Period after
Diagnosis

T-Test for Equality of Means

Assumption

Equal variances
assumed

F

Sig.

t

df

Sig.
(2-tailed)

10.282

.001

5.201

1493

.000

1.59693

30702

.99468

2.19917

32.682

2562.461

.000

1.59693

32462

.95691

2.23695

1.385

1431

.166

.22306

.16111

-.09298

.53910

4.900

1326.000

.000

.22306

.04552

.13376

.31236

Equal variances
not assumed

Referrals + 90- Equal variances
Day Lag
assumed
Period after
Diagnosis
Equal variances
not assumed

51.156

.000
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Mean
Sd. Error
Difference Difference

95% Confidence
Interval of the
Difference
Lower
Upper

Table 6: Comparison of Standard One-Way ANOVA and Independent-Samples T-Test (under ‘Equal Variances Assumed’)
Results

Diagnostic
Investigations

Referrals

27.054

1.917

.000

.000

.000

.000

.166

31.709

18.448

21.748

5.201

1.385

.000

.000

.000

.000

.166

Note:
√ANOVA F-value = t-value for independent-samples t-test (under ‘equal variances assumed’)
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Episode
Length (Days
to Diagnosis)

472.963

Referrals

340.336

Episode
Length (Days
to Diagnosis)

1005.477

Medications

Medications

IndependentSamples TTest (under
'equal
variances
assumed’)

Physician
Visits

Standard OneWay ANOVA
Test

Physician
Visits

Type of Test

Sig.

Diagnostic
Investigations

F/t-Statistic

Table 7: Comparison of Robust Tests of Equality of Means and Independent-Samples T-Test (under ‘Equal Variances Not
Assumed’) Results

Diagnostic
Investigations

Referrals

24.200

24.01

.000

.000

.000

.000

.000

BrownForsythe Test

1068.091

365.147

409.293

24.200

24.01

.000

.000

.000

.000

.000

32.682

19.109

20.231

4.919

4.900

.000

.000

.000

.000

.000

IndependentSamples TTest (under
'equal
variances not
assumed’)

Episode
Length (Days
to Diagnosis)

Medications

409.293

Referrals

365.147

Episode
Length (Days
to Diagnosis)

1068.091

Medications

Welch T-Test

Type of Test

Physician
Visits

Physician
Visits

Sig.

Diagnostic
Investigations

F/t-Statistic

Note:
√Welch t-test asymptotically F-distributed value = √Brown-Forsythe test asymptotically F-distributed value = t-value for independentsamples t-test (under ‘equal variances not assumed’)
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4.4 Objective Two: Magnitude of Effect. Effect Size Analysis.
Based on the findings across the four different effect size measures, the highest
level of consistency in the reported effect magnitude is demonstrated by the statistics that
rely on standard deviation units to present the difference between the two groups, i. e.,
Cohen’s d, Hedge’s g, and Glass’ delta. Not a single statistic of the three above indicates
a small size of effect for any of the five dependent variables.
The results of the eta squared, on the contrary, are indicative of a borderline
small/medium effect size (10%) for the number of medications prescribed and a very
small magnitude of effect for the diagnostic investigations ordered (only 2%). When the
eta squared findings for these two variables are compared to other effect size statistics,
the magnitude of the differences in the means is substantially higher, presenting a threelevel paradigm of effects. Specifically, the range of effect includes: 1) the medium effect
in Cohen’s d statistic for the diagnostic investigation variable; 2) the medium magnitude
of effect in Glass’ delta and Hedge’s g statistics for the medication and diagnostic
investigation variables, and 3) the borderline medium/large effect for the medication
variable in Cohen’s d statistic.
The results of effect size statistics are presented in Table 7. They are interpreted
entirely from a quantitative perspective, without any account of their practical relevance
and clinical significance in the context of an AF patient’s journey.
The Number of Physician Visits: The value of 0.27 or 27% of variance in eta
squared statistic is indicative of the large size of an effect by the group assignment. In
other words, 27 per cent of the total variation in the number of physician visits depends
on which group the patient is assigned to. Apart from the statistically significant
difference between the two groups, the measured effect index of 0.27 gives practical
importance to the finding.
The value of Cohen’s d = 1.23 indicates that the difference between the mean
number of physician visits in the AF group and the comparison group is larger than one
standard deviation, to be more precise, larger than 1.23 SD (large effect). Similarly, in
Hedge’s g and in Glass’ delta statistics, the magnitude of difference is larger than one
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standard deviation: 1.21 SD in Hedge’s g, 1.03 SD in Glass’ delta1, and 1.61 SD in
Glass’ delta2. Overall, for the number of physician visits as a dependent variable, the
effect size indices are consistent in the magnitude of effect being reported as large across
all of them.
The Number of Medications: For the medication variable, some degree of
inconsistency across the four effect size indices is observed. The eta squared value of
0.10 measures the 10 per cent proportion of variance in the number of medications that is
explained by the group assignment. Purely in quantitative terms, it is a borderline
small/medium size of an effect. At the opposite end of the spectrum is the value of 0.68
in Cohen’s d statistic that implies a borderline medium/large effect size. In the middle are
the values of Hedge’s g (0.66) and Glass’ delta statistics (0.61 and 0.76 for Glass’ delta1
and Glass’ delta2, respectively), with the reported medium magnitude of effect for both
indices.
The Episode Length (Days to Diagnosis): For the episode length variable, the
mean values for the two groups differ by 1.24 (Cohen’s d statistic), 1.29 (Hedge’s g
statistic), and by 1.17 and 1.33 (Glass’ delta1 and Glass’ delta2, respectively) standard
deviations. The eta square value of 0.22 (or 22%) is also highly suggestive of a large
effect size: the 22% proportion of variance in the episode length is due to the group
variable. The magnitude of effect is consistent throughout the four effect size indices.
Such results suggest that the length of an episode of illness varies substantially for a
patient depending on one’s group allocation.
The Number of Investigations: When applying the SD-based effect size measures,
i.e., Cohen’s d, Hedge’s g, and Glass’ delta, the effect size for the investigation variable
can be interpreted as medium. Only the eta square value of 0.02 (or 2%) indicates a small
association of variance in the number of investigations with the group allocation.
The Number of Referrals: As already mentioned, patients with chronic conditions
and co-morbidities are not often referred to specialty outpatient facilities for diagnosis.
Being referred to as “complex care physicians”, primary care physicians are heavily
relied on in terms of management of patients with high-cost chronic conditions.182 As a
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result, the allocation of a patient to an AF or a comparison group does not make much of
a variation as far as the diagnostic referrals are concerned. This status quo is reflected in
the low values of the effect size statistics (the eta square value of 0.001 or 0.1%; the
Cohen’s d value of 0.35; the Hedge’s g value of 0.28, and the Glass’ delta values of 0.59
and 0.13, respectively), thus indicating a very small effect size. Despite its high statistical
significance of the independent samples t-test, the difference between the two groups in
the number of referrals is although not trivial, but still very small.
By their original definition, our dependent variables have meaningful metrics that
are expressed by the number of physician visits, medications, referrals, diagnostic
investigations and days-to-diagnosis. These metrics are practically significant and
directly interpretable188 which is a great asset. However, IMB SPSS – like any other
statistical software – standardizes effect sizes. As a result, the original meaningful scale
of metrics is lost but standardized effect sizes (in this case, the proportion of variance in
percentage for the eta square statistic and standard deviation units for Cohen’s d, Hedge’s
g and Glass’ delta) are directly comparable across studies with different-scale
outcomes188.
The goal is ˗ despite the statistically significant differences between the AF and
the comparison groups in relation to the set of the dependent variables ˗ to quantify the
magnitude of those differences. In this sense, as rightfully stressed by Kline,188 the size of
an effect is a statistic “with a purpose of quantifying a phenomenon of interest”. The
rejection of a null hypothesis, by itself, does not guarantee substantive significance.
Kline180insists that clearly explicating the importance of the research findings in terms of
their clinical relevance and practical value for the patients is required.
The decision to use multiple effect size indices is a direct consequence of the
dilemma on how “to improve the communication of the results”188. The literature allows
reporting of multiple effect sizes that directly address the same research question to test
for the consistency of the effect size results. The choice of the effect size statistics is also
informed by the literature and is based on their commonality and relevance to the field of
research. D and r statistics have been chosen, with the d statistics describing mean
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contrasts in units of standard deviation and r statistic being a proportion of variance
explained effect size.188
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Table 8: Summary of Effect Size Calculations
Dependent
Variable

Independent
(Group)
Variable
AF Group

Sample
Size (N)

Mean

SD

1487

33.1742

19.04291

Eta
squared
(η 2 )

Cohen’s
d

Hedge’s
g

Glass’
delta1
( 1 )

Glass’
delta2
( 2 )

0.27
large

1.225344
(1.23)
large

1.207246
(1.21)
large

1.0287661
(1.03)
large

1.6071203
(1.61)
large

0.10
small/medium

0.675607
(0.68)
medium/
large

0.664028
(0.66)
medium

0.6128496
(0.61)
medium

0.7626766
(0.76)
medium

<0.001

0.22
large

1.243474
(1.24)
large

1.290954
(1.29)
large

1.1718251
(1.17)
large

1.3301078
(1.33)
large

<0.001

0.02
very small

0.413893
(0.41)
medium

0.425927
(0.43)
medium

0.3997957
(0.40)
medium

0.4295941
(0.43)
medium

Sig. (2tailed)

Physician
Visit
Comparison
Group

1287

13.5835

12.18994

AF Group

1845

21.1301

12.82827

<0.001

Medication

Episode
Length
(Days to
Diagnosis)

Comparison
Group

1327

13.2683

10.30817

AF Group

361

1019.27

391.782

Comparison
Group

1327

560.17

345.160

AF Group
Diagnostic
Investigation
+ 90-day Lag Comparison
Period after
Group
Diagnosis

168

4.8750

3.99429

1327

3.2781

3.71723

<0.001
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Table 8: Summary of Effect Size Calculations Continued
Dependent
Variable

Independent
(Group)
Variable
AF Group

Referrals +
90-day Lag
Period after
Diagnosis

Comparison
Group

Sample
Size (N)

Mean

SD

106

1.0000

.00000

1327

.7769

1.65819

Sig. (2tailed)

<0.001
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Eta
squared
(η 2 )

Cohen’s
d

Hedge’s
g

Glass’
delta1
( 1 )

Glass’
delta2
( 2 )

0.001
(almost no
effect)

0.354018
(0.35)
small

0.284381
(0.28)
small

0.5935433
(0.59)
medium

0.1345443
(0.13)
small

CHAPTER FIVE – DISCUSSION AND CONCLUSION

5.1 Strengths of Research
To the best of our knowledge, this has been one of the first studies to describe an
episode of AF illness in terms of the number of physician visits, the episode length, the
diagnostic investigations ordered, the medications prescribed, and the referrals made in a
primary care setting. The literature review did not identify any studies that are related to
the diagnosis of AF in the conceptual framework of an episode of care. Not only were
there no AF studies that would operationalize the episode of care as an appropriate unit
of assessment161, but also no current research explored time-to-diagnosis characteristics
in AF on a visit-per-visit basis. Using high-quality electronic medical records as a data
source for describing an AF episode of illness is another innovation. Given the rising
popularity of electronic health records systems and a profound shift of medical record
keeping from paper-based physicians’ notes to computerized modules, the methodology
employed in this research is transferable for use in other types of medical practice and
medical conditions.
The current research also contributes to quantitative research conducted from the
perspective of a patient rather than a health care provider. Choosing patient-important
outcomes helps to meaningfully map the patient’s journey to the diagnosis of AF in
quantitative terms. Previous research on other chronic conditions explored conditions of
interest within an episode of care. The focus of this study, however, is on an episode of
illness that should be clearly distinguished from both an episode of disease and an
episode of care.
In order to capture the patient’s experience in navigating the Canadian health care
system with the ultimate goal of diagnosis establishment, this research has a look-back
period of up to 4 years and specifies a distinct end-point. Such an approach of including
complete episodes of illness allows to explore patterns of health care utilization in AF
diagnosis. The research results can be of interest to different stakeholders ˗ patients,
physicians, policy makers and governmental agencies – as they identified the gaps in the
diagnosis of a chronic condition that can be addressed in future research.
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In the modern context, general practice is a complex care entity that is heavily
relied on for diagnosis and management of high-cost chronic conditions. That is why
recognizing patients’ challenges, identifying gaps on an upstream, system level and
facilitating positive downstream changes as well as stimulating a shift in professional
culture are key.

5.2 Limitations of Research
A major limitation of this research is the source of data itself. Electronic medical
records (EMRs) were developed to collect data for the purpose of individual patient
care, not for the purpose of research. As a result, the same type of information can be
stored in multiple places in the database. A number of terms can be used to denote the
same condition or phenomenon. In such a case, the researcher develops a list of related
terms and verifies it for completeness by examining each description to ensure that no
related terms are omitted. At the same time, clinically irrelevant – yet valuable for
research – information may not be found in EMRs. In an attempt to locate, extract and
analyze data, researchers have to explore all possible locations in an electronic medical
record which might not be feasible.
The dependent variables that were used imply some degree of uncertainty in data
interpretation. For instance, a patient may or may not express all the reasons for
encounter in the form of symptoms, complaints and requests for medical procedures.
This is particularly true now when patients are asked to restrict their encounter with a
physician to one major concern. The physician, on the other hand, is an initial recipient
of the patient’s information who exercises judgments on what to record in the database,
based entirely on situated and fragmented pieces of information189. This may or may not
lead to depiction of complete patient information. The question remains open how
concordant the patient self-report and the medical record are.
Another important limitation of this research that is beyond control is a lack of
definitive, proven information on the variables of interest: the number of physician
visits, the medications prescribed, the diagnostic investigations ordered and the referrals
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made. Hoping to meet current clinical guidelines, family doctors record is what
recommended or prescribed to patients. The actual result of a physician-patient
encounter remains unknown. It does not necessarily translate into the patient’s
compliance to the treatment protocol. Other external factors such as long wait lists for a
specialty outpatient service (in case of referrals) may cause patient non-compliance. A
patient is prescribed a medication but whether the prescription is filled is not known.
Similarly, a diagnostic investigation is ordered for a patient but there are no readily
available means of confirming that the investigation was conducted.
The logical consequence of the two previous points ˗ the “uncertain” and
“unknown” nature of medical data - is its incompleteness. The researcher cannot be sure
if the data are missing as such (in terms of medications, referrals and investigations) due
to the physician’s failure to record them or whether there have been truly no referrals
made, no diagnostic investigations ordered, and no medications prescribed.
Finally, we cannot establish a distinct start point of an episode of illness due to
transiency of symptoms in AF. That is why the decision has been made (and justified in
more detail in the Methods chapter) to use all of the available look-back period when
determining the boundaries of an episode of AF illness. This may overestimate the
duration of AF if the presenting symptom was not AF-related and AF first occurred at a
later date.

5.3 Objective One: Characteristics of an Atrial Fibrillation Episode of Illness
5.3.1 Number of Physician Visits
As already mentioned, no literature on characterizing an episode of AF illness in
the context of the dependent variables used in this thesis has been identified. With AF
being a chronic condition, we decided to compare our findings with the reported results
of the studies on other chronic conditions in family practice. Since the comparison group
consists of patients with the nine most common chronic conditions, the search was
extended to include any relevant information on those nine conditions.
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As is evident from the published research on the 14 highest-cost chronic
conditions in the USA182, a majority of patients seek care for their chronic conditions
from a generalist (69%) rather than a specialist physician (24%).
It is increasingly recognized that primary care medicine is distinctly different
with regard to pathologies, patients, and clinical presentations general practitioners deal
with in comparison with their specialty outpatient colleagues. The populations in general
practice are relatively unselected190. Rigid diagnostic labelling is less important than
deciding on an appropriate course of action. For instance, the use of a specific diagnosis
can be simply a justification of antibiotic treatment instead of its reason191. The so-called
diagnostic uncertainty is not the new Achilles’ heel of general practice, as
metaphorically labelled by Howie in 1972191, but rather an inherent, salient feature of a
primary care setting192. Often, family physicians frame their diagnostic decisions in
dichotomous terms: referral versus non-referral, diagnostic investigation versus no
diagnostic investigation, and treatment versus non-treatment.
The current research yields some insights with reference to the number of inoffice physician visits between the AF and comparison groups. Patients awaiting the
diagnosis of AF have, on average, 2.5 times more visits than patients with other
undiagnosed chronic conditions. In the context of family practice, it is still unclear why
this happens.
There are a number of possible explanations for the observed difference in the
number of physician visits between the two groups. A plausible explanation would be
the asymptomatic and transient nature of symptoms in AF. It takes time for the disease
to declare itself in the form of signs and symptoms. Or, on the contrary, the diagnosis of
AF is established incidentally with no related reason for encounter recorded in the
EMRs when the patient is completely asymptomatic. Another possible explanation is the
presence of multi-morbidity that clouds the clinical picture.192 When comparing the two
groups in the current work in terms of other chronic conditions , we can explain the
substantive difference in the number of physician visits due to the older age of the AF
group with a larger number of associated chronic conditions. These differences are
presented by both statistically significant t-test results and by a large effect size.
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5.3.2 Episode Length
The dependent variable of the episode length is directly connected to the number
of physician visits. It is also associated with the visit continuity on patients’ experience
with care193. It would be valuable to understand whether visit continuity is beneficial to
AF patients.
Little do we know about the realized and potential wait time to diagnosis. In a
situation when the patient does not present with any observable signs and reports no
symptoms, there is technically no wait time to diagnosis. The biggest obstacle in
“recognizing the zebras among the horses” is inability to rigidly define a starting point
of an AF episode of illness that would be measurable and expressed in standardized
terms. Even developing typical scenarios or patterns of diagnostic steps is problematic.
As McWhinney has pointed out, in the situated, community-based context, the focus of a
primary care physician is on patient management and not so much on diagnosis
establishment190.
The key defining feature of general practice is its holistic approach towards
disease and illness194. The patient’s journey to diagnosis is intertwined with the context
of an individual’s life experience and circumstances, including a myriad of diverse,
hardly quantitatively measurable factors such as social, environmental, occupational,
developmental, etc. Manipulations and tools of any sort (physical examination,
diagnostic testing, referrals) are only assistive devices for a family doctor to define a
“whole person diagnosis” of patient problems195 from a biopsychosocial perspective.
The question is, however, whether early diagnosis and intervention may
favourably impact the prognosis38. AF is recognized as a progressive disease that
generally evolves from paroxysmal through persistent to “permanent” forms38.
Theoretically, earlier diagnosis and timely intervention might limit or prevent the
disease progression. Furthermore, a personalized approach to the disease management
entails a treatment plan that is tailored to an individual’s risk factors, pathophysiology,
and genetic predisposition196. Nattel et al.38 believe that earlier diagnosis and treatment
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of AF can also prevent serious long-term complications such as blood clot formation,
stroke, heart attack, heart failure, and sudden cardiac arrest.
Clinical efficacy of early therapy warrants confirmation. If it can be shown that
more proactive diagnosis and treatment prevent progression and complications of AF,
intensive ECG monitoring could be established as a clinically relevant screening tool.

5.3.3 Medication
Based on our findings, medications are prescribed for the AF group of patients,
with a mean of 21.1 and standard deviation of 12.8. When compared to the control
group, AF patients tend to get by 50% more medications than the individuals living with
other chronic conditions (mean of 13.27 and standard deviation of 10.31).
Our findings are consistent with some previous studies. Of particular interest are
the results of the 2008 Commonwealth Fund International Health Policy Survey
conducted among eight industrialized nations: the United Kingdom, Canada, the United
States, Australia, New Zealand, Germany, France, and the Netherlands172. This survey
builds on an annual series that informs government health policies in the surveyed
countries. This international study focused on experiences of chronically ill patients with
complex health care needs. Among the major inclusion criteria were presence of chronic
disease(s) and frequent contact with the health care delivery system, including
hospitalizations and major surgeries within the last two years. The AF patients took six
or more prescription medications regularly whereas 30-50% per cent of the international
cohort of the participants reported taking four or more medications.
These findings are expected as they reflect the high dependency of chronic
patients on medication for disease management. In spite of the complicated medication
regimens, approximately 40% of the respondents were concerned by a lack of medical
supervision when neither primary care physicians, nor pharmacists reviewed their
medication lists172.
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5.3.4 Investigation
The most common type of diagnostic investigations was an X-ray of different
body parts. ECG comprised a relatively small proportion (less than 15%) of the total
number of investigations. Among other utilized diagnostic investigations were
ultrasound and computerized tomography scans of different body parts.
These findings resonate with characteristics of a family practice model that are
commonly described in the literature. For instance, primary care physicians are
estimated to diagnose a conventional disease in approximately 50% of patients
presenting to their offices197. In another study, after a 6-month follow-up period, only
50% of the patients with chest pain were told the cause of their disease198. The numbers
were even lower in another study in which only 20% of ambulatory male patients with
abdominal pain were ascribed a definitive diagnosis199.
Apparently, within the framework of family practice that “includes primary,
comprehensive, continuing, community-based, patient-centred, and preventive care”,
diagnostic investigations are useful in a small proportion of 5% of cases200.
As becomes clear from the above mentioned examples, although a part of family
practice, radiological and laboratory investigations have a limited role, leading to the
diagnosis establishment in 2-3 cases of every hundred of patients.
The general tendency that can be easily observed by a patient visiting one’s
physician’s office or even an emergency department in hospital is a selective use of
diagnostic testing for the sake of avoiding diagnostic inefficiency, i. e., unnecessary,
excessive testing, and over-diagnosis. In fact, over-diagnosis can have very similar
untoward consequences as under-diagnosis does. A striking example comes from the
study on diagnosing organic heart disease in children: false positive cases demonstrate
as much deterioration in social and physical function as children who do have the
disease201.

5.4 Objective Two: Effect Size in Study Group and Comparison Group
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In terms of the effect size, it is important to consider not only the magnitude for
each variable of interest but also the clinical relevance and practical value. Per se, a
“small” or “medium” clinically relevant effect size is more important than a “large”
effect of less practical value. It is more so a context-dependent judgment call.
We are aware of criticisms of so-called “T-shirt effect sizes”202 when standardized
magnitudes of effect are arbitrarily labelled as “small”, medium”, and “large” and applied
with little considerations of a particular context. Not withstanding the context-dependent
aspect of the effect magnitude, we purposively interpret effects with the rigor of
significance testing. It is an experimental, purely quantitative type of research, and
contextual analysis is outside its realm of expertise. Cohen203 suggested threshold values
of effect magnitude in behavioral research as a general rule of thumb rather than a readyto-use recipe. These values are arbitrary and should not be interpreted rigidly204. No
existing related literature on the effects of our variables of interest in a primary care
setting has been identified. Therefore, we cannot interpret our effects in explicit or direct
comparison against the published effects, as recommended by Thompson204.

5.5 Generalizability of Results
5.5.1 Representativeness of DELPHI Population in Comparison to General
Practice Population
In spite of a relatively small sample of AF cases, the DELPHI database is largely
representative of Ontario general practice patients and therefore, the results being
generalizable to a Canadian primary care setting. Below is the comparison of prevalence
of such patient-important outcomes as AF and stroke between the DELPHI database and
the current literature. The DELPHI descriptive statistics presented in Appendix K is
consistent with the age and sex distribution of AF patients and prevalence of AF by age
group in the general population.
As a recognized independent risk factor for stroke, AF accounts for at least a 5time increase in its incidence.205, 2,206, 207 Overall, the literature suggested 2-3% per year
of an absolute risk of stroke in the adult population versus 10-12% risk in patients with a
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previous cerebrovascular accident.208 Thus, 679 out of 48096 patients with stroke were
identified in the DELPHI database that corresponds to 1.4%. Among 1500 patients with
AF in the DELPHI database (Appendix K), 140 of them (9.3%) had a stroke: 62 females
and 78 males.
The ten-year prevalence of AF in the DELPHI database is 3.1% that rose steadily
with age up to the 80-89 age group (Appendix K). The majority of large studies
conducted in North America and Europe reported a prevalence of 0.4% to 3.9%.
Notably, such variation in the disease prevalence can be explained by a number of
factors: 1) hospital-based studies209,210 showed higher rates of AF than community-based
ones; 2) studies conducted in different ethnic populations such as African Americans2,
211

and Indo-Asians212 and in different geographical areas213, 209, 210 yielded a variety of

prevalence estimates; 213, 209, 210 3) differences in age stratification as well as inclusion of
limited age ranges214 can explain considerable variance of AF prevalence.
To demonstrate DELPHI feasibility in answering a specific research question and
its representativeness of general practice, the DELPHI prevalence values for AF were
compared to the ones from large studies across the world that were similar to the
DELPHI database in crucial parameters.
The eight-year overall prevalence of AF in the adult population, based on the
Clalit Heath Services computerized database of 2 420 000 adults (Israel), was 3%. It was
a methodologically sound study that was conducted in the population older than 20 years
of age and included both community and hospital diagnoses of AF.
Another large, population-based study that was conducted in Sweden with similar
patient populations reported a prevalence of 3.2%. The data were extracted from primary
healthcare, specialized outpatient, hospital drug registries in a Swedish region with 1.56
million residents215.
A study conducted by German researchers aimed at quantifying age- and genderspecific prevalence of AF in Germany.216 A database covering a large patient population
of all ages (8.298 million members of two German statutory health insurance funds) was
analyzed and the reported prevalence was 2.132%.
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5.5.2 Compatibility of the DELPHI Database with Other Electronic Medical
Record Databases
The DELPHI database is designed in the same structure as the nation-wide
electronic medical record surveillance database called “CPCSSN” (the Canadian Primary
Care Sentinel Surveillance Network). Therefore, the DELPHI database is fully compatible
with CPCSSN. The DELPHI database can be used as a pilot test platform of data search
fields as well as diagnostic and treatment algorithms for a variety of diseases. Following
initial statistical analyses of DELPHI findings, researchers can shift towards examining
region-determined commonalities and differences across primary care experience of
Canadians for a specific disease.
In its coding major types of structured data ˗ symptoms, diseases, and interventions
– the DELPHI database is similar to larger UK-located databases, specifically, to the
General Practice Research Database in the United Kingdom158.
Although available now in 19 languages, the core of a computer-based patient
record classified with ICPC is language independent. This allows comparisons of data from
different countries161. Furthermore, it develops family medicine to a profession with a welldefined and empirically based framework of reference161, 159.
Another operational characteristic of the DELPHI database is its inherent capacity
to monitor preventive care and chronic diseases that is similar to the US databases217, 218.
The feature that is unique to the DELPHI database is that it makes it possible to pose health
service-related questions and answer them. The examples of such would be the scope of
interdisciplinary care, wait times and workload157.
In order to create a researchable database, regular data quality assessment and
collaboration with information technology specialists are warranted157. After the DELPHI
database was populated with extracted data, a data quality assessment system was initiated.
This ensures that the data are complete and standardized across the participating sites, i. e.,
suitable for research purposes157.
Given data access by researchers, EMR data have several important advantages for
research157. First, longitudinal data enable researchers not only to explore a natural course
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of various diseases that are treated in general practice but also to follow patterns of care
delivery over time. Second, the DELPHI database is particularly useful in monitoring
preventive care and chronic disease management. This aspect of usefulness was also
touched upon in several US studies217, 218. Third, data can be collected, extracted and stored
relatively quickly. Overall, EMRs are a reliable source of information on various aspects of
primary health care.

5.5.3 Comparison of ICPC-Coded DELPHI Population and 2016 Canadian
Census Population
The comparison of ICPC-coded DELPHI population is made to the 2016
Canadian Census population. It was a seventh quinquennial census conducted by
Statistics Canada on May 10, 216. The 2016 Canadian Census presents the most recent
detailed enumeration of the Canadian residents. It counted a population of 35,151,728
which was a 5-per cent increase from the 2011 population of 33,476,688.
When compared to the 2016 Canadian Census population, the DELPHI ICPCcoded population is generally older and has a slightly higher proportion (by 5%) of
female patients. In Appendix L, the median age of 54 years in the ICPC-coded DELPHI
population is higher than the median age of 40 years reported by the 2016 Canadian
Census219. The proportion of female population in the ICPC-coded DELPHI project is
by 5% higher (56%) in comparison to the 51% from the 2016 Census.
The fact that more older females comprise the DELPHI population brings into
consideration the umbrella term of “the complex older patient” in general practice220.
This concept includes a number of social, psychological and medical problems221. In
broad strokes, complex patients, i. e., individuals with a few comorbidities and
functional disabilities, prefer to live in the community as long as possible rather than
being placed into residential facilities. This tendency is, in turn, reflected in higher
numbers of patients with several concurrent problems whom physicians see in their
practices221.
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As well documented in previous research220, older individuals and females are
more likely to be included into clinical samples as they tend to visit their physicians
more often than the general population. However, this discrepancy in age and sex
distribution does not indicate that the DELPHI population is different from the Canadian
population, overall. The reason is that the ICPC-coded DELPHI population represents a
random sample of patients who seek medical care from their family physicians.

5.6 Policy Implications
It is increasingly recognized that heath care delivery systems all over the world
are facing the challenge of aging, chronically ill patients with complex care needs. The
growing burden of care is falling on primary care physicians. However, the degree to
which general practitioners are relied on in providing patient-centered care, might be
neither realistic, nor fully appreciated222. The increasing societal demands and public
expectations of the quality of medical service can make it impossible for physicians to
meet all expectations. It is within the realm of family practice to screen patients and
identify their needs, to offer preventive services and provide education, to work with
communities and to stimulate behavioral changes182. This list is far from exhaustive. The
topic being debated within the last few years is whether there is time for managing
patients with chronic diseases in primary care. Ostbye et al.223 calculated that in order to
be compliant with current clinical guidelines of managing hypertension and diabetes, a
physician would need about 10 hours per day to care for each patient with multimorbidities.
This study is a first step towards identifying common areas of overlap in terms of
factors, barriers and facilitators of the AF patient’s journey towards diagnosis in the
primary care setting. Developing a detailed, multi-level knowledge transfer plan based
on consultation, involvement and partnership with key stakeholders - patients,
caregivers, healthcare providers and multi-disciplined researchers – can facilitate
positive changes in the current clinical guidelines for diagnosing and managing AF.
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5.7 Future Research
Patients’ experiences of arrhythmia diagnosis extend across multiple health care
sectors. For the majority of them, however, the initial diagnosis and management of AF
will be conducted in primary care,29 with the family doctor’s office being a starting point
of a patient’s journey. In Canada, primary care physicians serve as gatekeepers for further
referrals and diagnostic investigations. The primary care setting continues to be a
coordinating site of patient care. That is why the focus of this research is on mapping
patients’ experiences using electronic medical records (EMRs) that are accessed through
the DELPHI database. The data collected from the physicians’ offices was used to
describe a patient’s journey in quantitative terms.
It is quite an endeavor to tell a story behind the numbers when patients’
experiences are explored solely quantitatively, with the use of a database. With qualitative
research, on the contrary, a patient’s journey can be captured and mapped through focus
groups, surveys and in-depth narrative interviews. Although it is outside the scope of this
thesis, further qualitative and mixed-methods research is warranted. It can provide
knowledge of the context by documenting various aspects of a patient’s life between
interactions with the health care system. Ideally, we would like to know more about the
life of AF patients between doctor visits. The contextual approach might facilitate more
meaningful interpretation of patient history records, physician notes and questionnaire
scores.
For future research, an overarching goal could be to appreciate patients’ stories
behind the numbers, hear their voices and acknowledge patients’ right to fully participate in
the planning and delivery of patient-centered care. To do so, it is important to understand
what it is like for common Canadians to live with a potentially serious condition and seek
medical care from their physicians. By assessing similarities and differences across a
diversity of patients’ experiences, the researcher can potentially inform patient-centered
care, advocate for quality control initiatives and account for context-level quality of life
determinants.
Another important aspect to consider for future research is the socio-economic
impact of atrial fibrillation on individuals and their families. What we need to further know
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is an associated public health implication and its various aspects. To name a few, it would
be valuable to explore opportunity costs for patients and care givers, quality of life
variables (both physical and psychological), health care system utilization such as doctors’
referrals to tertiary care facilities, atrial fibrillation hospitalizations, emergency department
visits, etc.
An interesting opportunity within the qualitative realm could be participatory
action research. Patients with the experience of living with AF engage in the research
process and provide some insights by thinking critically, yet in a distance from their own
stories of a patient’s journey to diagnosis. This type of inquiry empowers participants to
co-manage the research cycle – from its conceptualization to the completion and
knowledge translation phases. The patient-led research could potentially identify unmet
needs and concerns as well as define patient-important outcomes rather than have them
imposed on the participants by the researcher(s).

5.8 Conclusion
Being the most common sustained cardiac arrhythmia, AF can carry substantial
health risk and thus has important public health implications. This was the first study to
explore AF episodes of illness in terms of the episode length, the number of physician
visits, the medications prescribed, the referrals made, and the diagnostic investigations
ordered in general practice.
All the findings were statistically significant, with reported large effect sizes.
Recognizing the limitations of establishing a precise starting point in the episode of AF
and whether initial symptoms were AF-related, it was on average, between 1.5 and 3
years and after multiple visits that the majority of patients received a first-time diagnosis
of AF. Patients tend to take multiple medications on a regular basis not only for the
suspected AF but also for other pre-existing comorbidities.
Further qualitative and mixed methods research can provide an in-depth situated
knowledge of the patient’s journey by documenting various aspects of their lives
between physician visits. The contextual approach could allow meaningful interpretation
of patient history records, physician notes and questionnaires scores.
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APPENDIX A: List of Atrial Fibrillation-Related ICPC Diagnostic Codes
ICPC Code

ICPC Code Description

K78

Atrial fibrillation/flutter

K04

Palpitations/awareness of heart

K05

Irregular heartbeat other

R02

Shortness of breath/dyspnea

A11

Chest pain NOS (not otherwise specified)

K28

Limited function/disability

A04

Weakness/tiredness general

P01

Feeling anxious/nervous/tense

N17

Vertigo/dizziness

K77

Heart failure

K83

Heart valve disease NOS (not otherwise specified)

K84

Heart disease other

K29

Cardiovascular symptoms/complications other

K99

Cardiovascular disease other
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APPENDIX B: List of Chronic ICPC Diagnostic Codes
ICPC Code
A21
A23
A90
A93
A95
A96
B71
B72
B73
B74
B78
B79
B90
D90
D92
D93
D94
F74
F81
F83
F84
F93
F94
F95
H80
H83
H84
H86
K22
K73
K74
K76
K78
K82
K86
K87
K90
K91
K92
K95
K96
N70

ICPC Code Description
Risk factor for malignancy
Risk factor NOS
Congenital anomaly nos/multiple
Premature newborn
Perinatal mortality
Death
Lymphadenitis chronic/non-specific
Hodgkin's disease/lymphoma
Leukaemia
Malignant neoplasm blood other
Hereditary haemolytic anaemia
Congenital anomaly blood/lymph other
HIV infection/AIDS
Hiatus Hernia
Diverticular disease
Irritable bowel syndrome
Chronic Enteritis/ulcerative colitis
Neoplasm of eye/adnexa
Congenital anomaly eye other
Retinopathy
Macular degeneration
Glaucoma
Blindness
Strabismus
Congenital anomaly of ear
Otosclerosis
Presbyacusis
Deafness
Risk factor for cardiovascular disease
Congenital anomaly cardiovascular
Ischaemic heart disease with angina
Ischaemic heart disease without angina
Atrial fibrillation/flutter
Pulmonary heart disease
Hypertension uncomplicated
hypertension complicated
Stroke/cerebrovascular accident
Cerebrovascular disease
Atherosclerosis/peripheral vascular disease
Varicose veins of leg
Haemorrhoids
Poliomyelitis
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N74
N75
N76
N85
N86
N87
N88
N89
N94
N99
R79
R89
R95
R96
R97
S91
S97
T78
T80
T81
T85
T86
T89
T90
T92
T93
U85
W13
W15
W76
W85
X11
X88
Y13
Y72
Y85

Malignant neoplasm nervous system
Benign neoplasm nervous system
Neoplasm nervous system unspecified
Congenital anomaly neurological
Multiple sclerosis
Parkinsonism
Epilepsy
Migraine
Peripheral neuritis/neoropathy
Neurological disease other
Chronic bronchitis
Congenital anomaly respiratory
Chronic obstructive pulmonary disease
Asthma
Allergic rhinitis
Psoriasis
Chronic ulcer skin
Thyroglossal duct/cyst
Congenital anomaly endocrine/metabolic
Goitre
Hyperthyroidism/thyrotoxicosis
Hypothyroidism/myxoedema
Diabetes insulin dependent
Diabetes non-insulin dependent
Gout
Lipid disorder
Congenital anomaly urinary tract
Sterilization female
Infertility/subfertility female
Congenital anomaly complicating pregnancy
Gestational diabetes
Menopausal symptom/complaint
Fibrocystic disease breast
Sterilization male
Genital herpes male
Benign prostatic hypertrophy
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APPENDIX C: List of Musculoskeletal ICPC Diagnostic Codes
ICPC Code
L01
L04
L05
L07
L08
L09
L10
L11
L12
L13
L14
L15
L16
L17
L18
L19
L20
L28
L29
L70
L71
L72
L73
L74
L75
L76
L77
L78
L79
L80
L81
L82
L83
L85
L87
L88
L89
L90
L91
L92
L93
L94

Description
Neck symptom/complaint
Chest symptom complaint
Flank/axilla symptom/complaint
Jaw symptom/complaint
Shoulder symptom/complaint
Arm symptom/complaint
Elbow symptom/complaint
Wrist symptom/complaint
Hand/finger symptom/complaint
Hip symptom/complaint
Leg/thigh symptom/complaint
Knee symptom/complaint
Ankle symptom/complaint
Foot/toe symptom/complaint
Muscle pain
Muscle symptom/complaint NOS
Joint symptom/complaint NOS
Limited function/disability (L)
Musculoskeletal symptom/complaint other
Infection of musculoskeletal system
Malignant neoplasm musculoskeletal
Fracture: radius/ulna
Fracture: tibia/fibula
Fracture: hand/foot bone
Fracture: femur
Fracture: other
Sprain/strain of ankle
Sprain/strain of knee
Sprain/strain of joint NOS
Dislocation/subluxation
Injury musculoskeletal NOS
Congenital anomaly musculoskeletal
Neck syndrome
Acquired deformity of spine
Bursitis/tendinitis/synovitis NOS
Rheumatoid/seropositive arthritis
Osteoarthrosis of hip
Osteoarthrosis of knee
Osteoarthrosis other
Shoulder syndrome
Tennis elbow
Osteochondrosis
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L95
L96
L97
L98
L99

Osteoporosis
Acute internal damage knee
Neoplasm musculoskeletal benign/unspecified
Acquired deformity of limb
Musculoskeletal disease other
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APPENDIX D: List of Psychosocial ICPC Diagnostic Codes
ICPC Code
Code Description
Psychological
P01
Feeling anxious/nervous/tense
P02
Acute stress reaction
P03
Feeling depressed
P04
Feeling/behaving irritable/angry
P05
Senility, feeling/behaving old
P06
Sleep disturbance
P07
Sexual desire reduced
P08
Sexual fulfillment reduced
P09
Sexual preference concern
P10
Stammering/stuttering/tic
P11
Eating problem in child
P12
Bedwetting/enuresis
P13
Encopresis/bowel training problem
P15
Chronic alcohol abuse
P16
Acute alcohol abuse
P17
Tobacco abuse
P18
Medication abuse
P19
Drug abuse
P20
Memory disturbance
P22
Child behaviour symptom/complaint
P23
Adolescent behaviour symptom/complaint
P24
Specific learning problem
P25
Phase of life problem adult
P28
Limited function/disability
P29
Psychological symptom/complaint other
P70
Dementia
P71
Organic psychosis other
P72
Schizophrenia
P73
Affective psychosis
P74
Anxiety disorder/anxiety state
P75
Somatization disorder
P76
Depressive disorder
P77
Suicide/suicide attempt
P78
Neuraesthenia/surmenage
P79
Phobia/compulsive disorder
P80
Personality disorder
P81
Hyperkinetic disorder
P82
Post-traumatic stress disorder
P85
Mental retardation
P86
Anorexia nervosa/bulimia
P98
Psychosis NOS/other
P99
Psychological disorders other
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Fear
A25
A26
A27
B25
B26
B27
D26
D27
F27
H27
K24
K25
K27
L26
L27
N26
N27
P27
R26
R27
S26
S27
T26
T27
U26
U27
W02
W21
W27
X22
X23
X24
X25
X26
X27
Y24
Y25
Y26
Y27
Z27
Social
Z01
Z02
Z03

Fear of death/dying
Fear of cancer NOS
Fear of other disease NOS
Fear of AIDS/HIV
Fear of cancer blood/lymph
Fear of blood/lymph disease other
Fear of cancer of digestive system
Fear of digestive disease other
Fear of eye disease
Fear of ear disease
Fear of heart disease
Fear of hypertension
Fear of cardiovascular disease
Fear of cancer musculoskeletal
Fear of musculoskeletal disease other
Fear of cancer of neurological system
Fear of neurological disease other
Fear of mental disorder
Fear of cancer of respiratory system
Fear of respiratory disease other
Fear of cancer of skin
Fear of skin disease other
Fear of cancer of endocrine system
Fear of endocrine/metabolic disease other
Fear of cancer of urinary system
Fear of urinary disease other
Fear of pregnancy
Concern about boday image related to pregnancy
Fear of complications of pregnancy
Concern about breast appearance female
Fear of sexually transmitted disease female
Fear of sexual dysfunction female
Fear of genital cancer female
Fear of breast cancer female
Fear genital/breast disease female other
Fear of sexual dysfunction male
Fear of sexually transmitted disease male
Fear of genital cancer male
Fear of genital disease male other
Fear of social problem

Poverty/financial problem
Food/water problem
Housing/neighbourhood problem
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Z04
Z05
Z06
Z07
Z08
Z09
Z10
Z11
Z12
Z13
Z14
Z15
Z16
Z18
Z19
Z20
Z21
Z22
Z23
Z24
Z25
Z28
Z29

Social cultural problem
Work problem
Unemployment problem
Education problem
Social welfare problem
Legal problem
Health care system problem
Compliance/being ill problem
Relationship problem with partner
Partner`s behaviour problem
Partner illness problem
Loss/death of partner problem
Relationship problem with child
Illness problem with child
Loss/death of child problem
Relationship problem parent/family
Behaviour problem parent/family
Illness problem parent/family
Loss/death of parent/family member problem
Relationship problem friend
Assault/harmful event problem
Limited function/disability (Z)
Social problem NOS
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APPENDIX E: Measures of Effect Size

#

Measure of
Effect Size

Formula
𝑡2

1.

Eta squared

η 2= 𝑡 2 +(𝑁1+𝑁2−2)
Where:
• η 2 = eta squared
• t = t-value
• N1= sample size of
group 1
• N2= sample size of
group 2

Operational Definition
Eta squared measures the
proportion of variance in the
dependent variable that is
explained by the independent
(group) variable

Interpretation

Applicability

An eta squared value indicates
the proportion of the total
variation in a dependent
variable Y that is attributed to
an independent (group) variable
X.

tends to be biased in
overestimating the
size of effect in the
population

Eta squared threshold values:
0 – no association
0.26 – large effect size
0.13 – medium effect
0.02 – small effect
1 – perfect association
Can be expressed as a
percentage

,
2.

Cohen’s d

Cohen's d = (M2 - M1) ⁄
SDpooled

Cohen’s d presents the
difference between the groups
in terms of standard deviation
units.

Where:
• M1 = mean value for
group 1
• M2 = mean value for
group 2

Cohen’s threshold values of
effect magnitude:
0.20 – small, but not trivial
0.50 – medium
around or above 0.80 – large
If two groups’ means do not
differ by 0.2 standard
deviations or more, the
difference is trivial, despite its
statistical significance.
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appropriate if two
groups have similar
standard deviations
and are of the same
size; most
commonly reported
in medical research

•
•
•

3.

Glass’ delta

SDpooled = pooled
standard deviation
SD1 = standard
deviation for group 1
SD2 = standard
deviation for group 2

 = M1 - M2 / SD control
Where:
•  = Glass’ delta
• M1 = mean value for
group 1
• M2 = mean value for
group 2
• SD control = standard
deviation of the control
group
However, Kline180
recommends reporting
Glass’ delta twice - 1 and
2, using the standard
deviation of each group.

If the value of Cohen’s d is
larger than 1, the difference
between the two means is
larger than one standard
deviation (large effect).

Glass’ delta uses the standard
deviation of the comparison
group.
Using the standard deviation of
the comparison group in the
denominator is justified when
the standard deviation of the
control group is believed to be
a better estimate of the standard
deviation in the population to
which the study results are
inferred than the standard
deviation of the experimental
group is.
The logic is that the standard
deviation of the control group
is not contaminated by the
treatment effects and, therefore,
reflects more accurately the
population standard
deviation224.
The difference between the
groups is presented in terms of
standard deviation units
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If two groups’ means do not
differ by 0.2 standard
deviations or more, the
difference is trivial, despite of
its statistical significance.
If the value of Cohen’s d is
larger than 1, the difference
between the two means is
larger than one standard
deviation

an alternative
measure for groups
with substantially
different standard
deviations, i. e..,
with unequal
variance; also with
unequal comparison
group

4.

Hedge’s g

Where:
• g = Hedge’s g
• x1 = mean value for
group 1
• x2 = mean value for
group 2
• n1 = sample size of
group 1
• n2 = sample size of
group 2
• s1 = standard deviation
of group 1
• s2 = standard deviation
of group 2

Hedge’s g provides a measure
of effect size that is weighted
according to the relative size of
each sample. It
presents the difference between
the groups in terms of standard
deviation units.
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If two groups’ means do not
differ by 0.2 standard
deviations or more, the
difference is trivial, despite of
its statistical significance.
If the value of Hedge’s g is
larger than 1, the difference
between the two means is
larger than one standard
deviation.

used for unequal or
small sample sizes
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APPENDIX F: Manual Calculation of Effect Size: Eta Squared
The formula for eta squared is as follows:174
𝑡2

Eta squared = 𝑡 2 +(𝑁1+𝑁2−2)

Replacing with the appropriate values for each of the five dependent variables:
1) Eta squared (the number of physician visits as a dependent variable) =
32.6822

1068.113124

=32.6822 +(1487+1287−2) = 1068.113124+2772 =

1068.113124
3840.113124

= 0.2781462654

Eta squared = 0.28

2) Eta squared (the number of different medication names as a dependent variable) =
19.1092

365.153881

=19.1092 +(1845+1327−2) = 3535.153881 = 0.1032922168
Eta squared = 0.10

3) Eta squared (the episode length as a dependent variable) =
=

20.2312

20.2312 +(361+1327−2)

=

409.293361
2095.293361

= 0.1953394062

Eta squared = 0.20

4) Eta squared (the number of diagnostic investigations as a dependent variable) =
4.9192

24.196561

=4.9192 +(168+1327−2) = 1517.196561 = 0.0159482045
Eta squared = 0.02

Ever,
5) Eta squared (the number of referrals as a dependent variable) =
4.9002

24.01

=4.9002 +(106+1327−2) = 1455.01 = 0.0165016048
Eta squared = 0.02
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APPENDIX G: Semi-Manual Calculation of Effect Size: Eta Squared
IBM SPSS does not provide effect size statistics for t-tests in the output174. However, it is
possible to get an eta value through crosstabs in descriptive statistics. Below are the IBM
SPSS outputs with eta values for the five dependent variables.
1)

Eta (the number of physician visits as a dependent variable) = 0.516

2) Eta (the number of different medication names as a dependent variable) = 0.311

3) Eta (the episode length as a dependent variable) = 0.468

4) Eta (the number of diagnostic investigations as a dependent variable) = 0.133
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5) Eta (the number of referrals as a dependent variable) = 0.037

From the eta values above, we can manually calculate eta squared values for each
of the five dependent variables:
1) Eta squared (the number of physician visits as a dependent variable) = 0.5162 =
0.266256 = 0.27

2) Eta squared (the number of different medication names as a dependent variable) =
0.3112 = 0.096721 = 0.10
3) Eta squared (the episode length as a dependent variable) = 0.4682 = 0.219024 = 0.22
4) Eta squared (the number of diagnostic investigations as a dependent variable) = 0.1332 =
0.017689 = 0.02

5) Eta squared (the number of referrals as a dependent variable) = 0.0372= 0.001369 = 0.001
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APPENDIX H: Summary Table of Eta Squared Values

#

Dependent variable

1.

The number of physician
visits

SPSS
Calculated Eta
Value
0.266256
(0.27)

Manually
Calculated Eta
Value
0.2781462654
(0.28)

Magnitude of
Effect

2.

The number of different
medication names

0.096721
(0.10)

0.1032922168
(0.10)

small

3.

The episode length

0.219024
(0.22)

0.1953394062
(0.20)

medium

4.

The number of diagnostic
investigations

0.017689
(0.02)

0.0159482045
(0.02)

small

5.

The number of referrals

0.001369
(0.001)

0.0165016048
(0.02)

almost no effect

large

NOTES:
1

Eta squared ranges from 0 to 1174, 0 meaning “no association” and 1 representing “perfect

association”.
2

Eta squared measures the proportion of variation in a dependent variable that is related to

the membership of different groups defined by an independent variable (or a group
variable).
3

Eta squared assesses how much variation in the dependent variable is explained by

variation of the independent variable.
4
5

The variance can be expressed as percentage by multiplying an eta squared value by 100.
Interpretation scheme:

0 – no association
0.02 – small effect size
0.13 – medium effect size
0.26 – large effect size
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1 – perfect association
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APPENDIX I: Calculation of Cohen’s d
Using the information provided in the IBM SPSS output for the independent-samples ttest, i. e., mean and standard deviation values for both groups, and with the help of an
online calculator from https://www.socscistatistics.com/effectsize/Default3.aspx, we
calculated Cohen’s d for the five dependent variables.
The formula for Cohen’s d is as follows:
Cohen's d = (M2 - M1) ⁄ SDpooled

Where:
•

M1 = mean value for group 1

•

M2 = mean value for group 2

•

SPpooled = pooled standard deviation

•

SD1 = standard deviation for group 1

•

SD1 = standard deviation for group 2
1) Cohen’s d (the number of physician visits as a dependent variable) = (13.5835 33.1742) ⁄ 15.987918 = 1.225344.
2) Cohen’s d (the number of different medication names as a dependent variable) =
(13.2683 - 21.1301) ⁄ 11.636642 = 0.675607.
3) Cohen’s d (the episode length as a dependent variable) = (560.17 – 1019.27)/369.207639
= 1.243474.
4) Cohen’s d (the number of diagnostic investigations as a dependent variable) = (3.2781 4.875) ⁄ 3.858248 = 0.413893.
5) Cohen’s d (the number of referrals as a dependent variable) = (0.7769 1.2347) ⁄ 1.293155 = 0.354018.
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NOTES:
1Cohen’s
2A

d presents the difference between the groups in terms of standard deviation units.

negative sign before the value is uninformative of the effect size. The negative sign indicates

that there is a mean increase from one group to the other.
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APPENDIX J: Calculation of Hedge’s g
Using the information provided in the IBM SPSS output for the independent-samples t-test, i. e.,
mean and standard deviation values for both groups, and with the help of an online calculator
from https://www.socscistatistics.com/effectsize/Default3.aspx, we calculated Hedge’s g for the
five dependent variables:
The formula for Hedge’s g is as follows:

Where:
• g = Hedge’s g
•

x1 = mean value for group 1

•

x2 = mean value for group 2

•

n1 = sample size of group 1

•

n2 = sample size of group 2

•

s1 = standard deviation of group 1

•

s2 = standard deviation of group 2

1) Hedge’s g (the number of physician visits as a dependent variable) = (13.5835 33.1742) ⁄ 16.227598 = 1.207246.
2) Hedge’s g (the number of different medication names as a dependent variable) = (13.2683 21.1301) ⁄ 11.839563 = 0.664028.
3) Hedge’s g (the episode length as a dependent variable) = (560.17 – 1019.27)/355.628446 =
1.290954.
4) Hedge’s g (the number of diagnostic investigations as a dependent variable) = (3.2781 4.875) ⁄ 3.749238 = 0.425927.
5) Hedge’s g (the number of referrals as a dependent variable) = (0.7769 - 1.2347) ⁄ 1.609812 =
0.284381.
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NOTES:
1Hedge’s

g provides a measure of effect size that is weighted according to the relative size of
each sample.
2Hedge’s

g presents the difference between the groups in terms of standard deviation units.

3Hedge’s

g used for unequal or small sample sizes.

4Hedge’s

g results are deemed most valid as the AF and comparison groups have different

sample sizes.
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APPENDIX K: Representativeness of DELPHI Population

Prevalence of Atrial Fibrillation by Age Group
Age
(years)
0-9
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80-89
90-99
100+
Total

Number of
Patients
3510
3878
5669
5468
5477
7608
7190
5062
2970
1171
93
48096

Number of
patients with
atrial
fibrillation
*
8
33
33
55
129
250
402
425
157
6
1500

Percentage of
patients with
atrial
fibrillation
*
0.2%
0.6%
0.6%
1.0%
1.7%
3.5%
7.9%
14.3%
13.4%
6.5%
3.1%
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APPENDIX K: Representativeness of DELPHI Population Continued

Age and sex distribution of patients with atrial fibrillation
Gender

Mean
Age

Male
Female
Total

Number of
Patients
800
700
1500

Gender

Frequency

Percent

Male
Female
Total

800
700
1500

53.3
46.7
100.0

Mode of Patient
Identification
Continuous Patient
Profile
ICD9 code 427x
Both CPP and ICD9
Total

73.2
72.1
72.6

Standard
Deviation

Range

14.9 10-107
17.8 2-104
16.4 2-107

Valid
Percent
53.3
46.7
100.0

95% C.I.

72.2 -74.2
70.8-73.4
71.8-73.4

Cumulative
Percent
53.3
100.0

Number Percentage 95% C.I.
of
of Patients
Patients (%)
424
696
380
1500

28.3
46.4
25.3
100
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26.0-30.6
43.9-49.0
23.1-27.6
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APPENDIX L: Age and Sex Distribution in the ICPC-Coded DELPHI Population
(N=3,525) and the 2016 Canadian Census Population (N= 35,151,728)
Median
Age
(years)

Median
age Males
(years)

Median age
Females
(years)

% Males

% Females

Census
Population

40

39

41

49%

51%

ICPC
Population

54

53

56

44%

56%

NOTES:
N=3,525 - the sample of ICPC-coded patients coded from the Deliver Primary Health Care
Information (DELPHI) Project.
N=35,151,728 - the 2016 Canadian Census data from Statistics Canada219.
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